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1.0 Introduction 
1.1 Purpose and research method  
The purpose of this thesis is to investigate the current marketing practices of 
pharmaceutical companies through a literature search, case studies and interviews. 
The literature search focussed on the regulations and guidelines that control the 
promotion of pharmaceutical products in four markets; Europe, United States, 
Japan and Ireland.  
The two products that were investigated for the case studies are Claritin (Clarityn) 
from Schering-Plough and Lipitor from Pfizer. The case studies focussed on how 
the companies promoted and influenced patients to buy their products through 
television commercials and websites in order to keep their market share and 
maybe entice new customers to buy it. 
Interviews were done with a series of 10 questions with three doctors and three 
pharmacists to find out their opinions on current marketing practices of the 
companies, the influence of gifts from pharmaceutical representatives on 
prescribing or selling particular drugs and opinions on Direct-to-Consumer 
(DTC), internet advertising, and how this effects and controls their decisions on 
prescribing or selling particular brands of drugs.  
Interviews were also preformed with three pharmaceutical representatives to find 
out their opinions on their own positions within the pharmaceutical industry, their 
backgrounds, and their individual approaches in selling their particular products. 
Further opinions were sought from personnel from industry, a business 
effectiveness manager and a senior regulatory specialist. 
1.2 Pharmaceutical Marketing 
Pharmaceutical marketing is the business of advertising or otherwise promoting 
the sale of pharmaceuticals or drugs. Marketing plays a key role influencing or 
directing activities from the manufacturer to the patient. It is the demand from the 
consumer that determines which goods will be produced. Any pharmaceutical 
company that wants to serve its market has to endeavour in direct marketing 
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activities so that the right product is sold in the right quantity in the right place at 
the right time.  
According to Marketing Planning for the Pharmaceutical Industry by John 
Lidstone, the aim is to change from a non-usage of a product to usage or repeated 
usage. (30) There are different buying stages of healthcare professionals in which 
the pharmaceutical companies have to make their product known: 
Unawareness to awareness 
During this stage the product is not known at all by the doctor/pharmacist and in 
which the medicinal drug moves from no knowledge towards a situation where 
the healthcare professional knows about it. In this stage marketing has two 
purposes:  
 Telling the doctor that your product exists 
 Creating an association between the therapeutic area and the product 
Awareness to Interest 
This is a movement from a passive stage to an active stage of attention. The 
healthcare professional will have his curiosity motivated by the products‟ 
newness, appearance, or concept. The marketing objectives in this stage are: 
 Gaining his attention through promotion 
 Creating interest or a motivation towards the product 
 Providing a summary information of the product  
Interest to Evaluation  
At this stage, the professional will consider the effect of the product upon his 
motivations i.e. lifestyle or image. The healthcare professional will analyse, 
rationalize, and look for advantages with the new product. Depending on what the 
healthcare professional needs, such as improved efficacy, more economy, the 
uniqueness of the drug and safety. Marketing at this stage attempts to  
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 Encourages the doctor to start his study of the drug 
 Find the requirements of the healthcare professional 
 Segment and target the doctors according to the requirements of the professional  
Evaluation to Trial 
This is the key movement for the evaluation stage in which he/she is still 
considering the product to actually using it. Marketing from the company at this 
stage has to 
 Identify usage opportunities 
 Suggest the usage when the opportunities occur  
Trial to Usage 
When the trial is successful, the professional will move to usage in prescribing the 
product. The pharmaceutical company at this point has to: 
 Provide reminders of key elements such as brand, therapy area and the advantages 
of usage 
 Emphasise the success and the approval of prescribing the product 
 Remind the prospective subscriber of usage prospects and present proof of other 
doctors‟ usage and success.  
Usage to Repeat Usage 
This is the final objective for marketing. When a healthcare professional moves 
from the occasional use to constant use, they move into a stage of automatically 
selecting the particular prescription drug. At this stage the company has to: 
 Maintain the environment that has led to satisfaction 
 Keep a satisfactory image 
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 Keep confirming and reminding the healthcare professional of the key qualities of 
the product  
During these stages of marketing a drug, pharmaceutical companies in their 
pursuit of increased profits, can use unethical methods to push their products. 
From the first stage of introducing the product, right through the final stage of 
usage to repeated usage, the company will try to influence the healthcare 
professionals‟ choice in choosing their particular product. 
1.3 Advertising  
Pharmaceutical advertising has some similarities and some distinct differences 
from the advertising of consumer goods. The marketing behaviour of 
pharmaceutical companies is in which the advertising is directed towards the 
prescribers rather than the final consumer but in some countries, direct-to 
consumer (DTC) marketing is standard, specifically the United States and New 
Zealand. (1) Forms of DTC advertising include television, print, radio and 
other mass and social media. There are concerns regarding DTC advertising, 
specifically the extent to which these advertisements may unduly influence the 
prescribing of the prescription medicines based on consumer demands when, in 
some cases, may not be medically necessary. As such, in the United States and 
New Zealand, there are regulations and guidelines that control this type of 
advertising. 
The pharmaceutical industry has not been as quick as other sectors to accept 
digital marketing, partly due to unclear guidelines from the FDA. But many DTC 
marketers are beginning to recognize the opportunities that the new media offers 
for reaching consumers. Budgets are still allocated to traditional media such as 
television, newspapers, magazines and radio but marketers are beginning to shift 
some of their spending to digital activities such as product websites, online 
display advertising, search engine marketing, social media campaigns, and mobile 
advertising. (45) 
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1.4 Labelling 
Summary of Product Characteristics (SPCs)/Patient Information Leaflets 
(PILs) 
Patient Information Leaflets (PILs) 
Patient Information Leaflet is a document provided along with a prescription 
medication to provide additional information about that drug. 
The first information that‟s listed is usually the brand name, the quantities of the 
drug available and generic name of the product.  
The other sections are as follows: 
Important things that you should know about your medicine – this section 
outlines the most important things that the patient needs to know about the drug. 
What the drug is and what it is used for – this describes what the drug is and a 
description of what it is used for. 
Before you take the drug – this is any warnings about interactions with other 
drugs and if you had any other diseases age restrictions etc. 
How to take the drug – this section tells you what doses of the drug you can 
take, if you overdose on it and if you miss a dosage 
Possible side effects – any side effects that could happen 
How to store – how to store the drug and to keep it out of the reach of children 
Further information – this section gives the patient a description of the drug and 
the pack. 
Marketing Authorization Holder and Manufacturer – the name and address of 
the Marketing Authorization Holder and Manufacturer 
The date when updated is the last item on the PIL. 
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Figure 1: Example of a Patient Information Leaflet 
Summary of Product Characteristics (SPCs) 
When a product is granted an authorisation by the regulatory authorities allowing 
it to be sold or supplied,  that authorisation contains a document known as the 
summary of product characteristics (SPCs), the wording of which has been agreed 
with the regulatory authority as part of the regulatory approval process. The SPC 
is designed to assist doctors and pharmacists in prescribing and supplying the 
product and describes what's in the product, what it's used for, the dose, side 
effects and so on.  
The information in the SPC comes under a number of headings: 
Name of the Medicinal Product 
The brand name of the product, usually registered as a trademark by the 
manufacturer. There may be more than one brand available of the same drug.  
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Qualitative and Quantitative Composition 
The generic or chemical names of the active ingredients and the amount of each 
active ingredient e.g. amount per tablet, amount per ml of solution, etc. 
Pharmaceutical form 
The physical form in which the medicine is presented, e.g. tablets, suppositories, 
ointment etc. 
Clinical particulars 
How the medicine should be used or taken. This section includes:   
 Therapeutic indications - The diseases or conditions that the medicine is 
licensed to treat. 
 Posology and method of administration - Information on the dose and how 
and when the medicine should be used or taken. Details are maybe included 
are the changing dose with age or other diseases and the maximum dose that 
can be given. 
 Contraindications: Any situations where a medicine should either are 
definitely or generally used. 
 Special warnings and precautions for use - any situations where a medicine 
should be used carefully, e.g. in patients with kidney or liver disease or elderly 
people. 
 Interactions with other medicinal products and other forms of interaction - 
details of any medicines that are known to or may react when taken together, 
as well as potential interactions with food or alcohol if relevant. 
 Pregnancy and lactation - information on the risks of using the medicine 
during pregnancy or breast-feeding. 
 Effects on ability to drive and use machines - whether or not the medicine is 
likely to alter the user's performance, particularly if it will affect the ability to 
drive or operate machines. 
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 Undesirable effects - the side effects you might have with the medicine, how 
likely the side effect is to occur, how severe it may be, and how long it might 
last for. 
 Overdose - what may happen if you take or use too much of the medicine and 
what the doctor should do in this situation. 
 Pharmacological properties - How the medicine affects the body. This section 
includes 
 Pharmacodynamic properties - How the medicine achieves, or is believed to 
achieve its therapeutic effect in the body. 
 Pharmacokinetic properties- information on how the medicine is absorbed and 
distributed in the body and then removed. 
 Preclinical safety data- any effects of the medicine that have been found from 
laboratory or animal studies, before it was used in humans, which could be 
relevant. 
Pharmaceutical properties 
This is information on the medicine's ingredients, storage and packaging. This 
section includes: 
 List of excipients - the non-biologically active ingredients of the medicine, 
such as binding agents, preservatives, flavourings, etc. 
 Incompatibilities - in addition to the information already given in 
Interactions with Other Medicinal Products and Other Forms of 
Interactions, this section gives information on any other medicines that 
shouldn't be mixed. 
 Shelf life - the maximum length of time for which the medicine may be 
stored under the specified conditions. It should not be used after this date. 
 Special precautions for storage - how the medicine should be stored. 
 Nature and contents of container - information on the medicine's 
packaging, including anything else you may find in the pack.  
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 Special precautions for disposal and other handling - information on the 
correct disposal or other handling of the product. 
Marketing authorisation holder 
The name of the company that is originally authorised to market the medicine. By 
commercial arrangement, the medicine may subsequently be marketed and 
distributed by another company. 
Marketing authorisation number(s) - This is the number of the marketing 
authorisation for the medicine granted by the licensing authority.  
Date of first authorisation/renewal of the authorisation - The date when the 
marketing authorisation was first granted or last renewed. 
Date of revision of the text - The last date on which a change to the wording of 
the SPC was made, e.g. a new side effect or a new pack size added. These 
changes must be approved by the regulatory authority that granted the marketing 
authorisation. There may not have been any changes to the text since the 
marketing authorisation was granted or renewed, in which case this section will 
be blank.  
1.5 Branding  
Branding is identified as a creation of a bond with customers through a 
distinguishing approach and in a manner that is consistent with the promise of the 
brand. According to the American Marketing Association, “a brand is a name, 
term sign, symbol, or design or a combination of these intended to identify the 
goods and services of one seller or group of sellers and to differentiate them from 
those of competition.” (40)  
There are two types of branding: product brand and company brand. The 
company brand is based on one name and one name alone. The name of the 
company is perceived to be the best candidate for brand name as it personifies 
power continuity and status. Product brand is when the company carves up and 
fragments the market. Mainly focused on in the pharmaceutical industry is 
promoting the product brand but the company brand maybe utilized as well. The 
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company brand has to be used to build trust in “target” therapeutic areas while the 
product brand is used to differentiate itself from the other products in this 
particular therapeutic area, influencing the company brand as its source of 
superior authority. (41) 
Branding is important due to therapeutic areas becoming crowded with different 
product offerings. The global generics market has expanded due to the increasing 
amount of patents that are expiring. Branding offers an opportunity to 
differentiate from this increasing competition and pressure on pricing. Patients 
have been increasingly involved with the prescribing decisions through the doctor 
and would influence their decision mainly through DTC advertising. Supporters 
say that the DTC advertising makes the patient more knowledgeable about 
treatments and therefore make them go for a particular brand. (41) 
The pharmaceutical industry already possesses some strong, well-known, well-
established brands, with a large number that enjoy little or no patent security. 
Brands such as Prozac and Clarityn continue to be important to their companies, 
because during their years of exclusiveness they created a force in demand. This 
drive helped them to cushion against the eventual arrival of generic competition. 
Each brand has now become so well known that it stands for a set of distinct 
characteristics and benefits, the net impact is the belief in the minds of the 
prescribers, pharmacists and consumers is that the brand is superior to the 
incoming generic competitors. In a competitive situation, this belief can‟t be 
strong enough to justify paying more, but with parity with the generic drug prices, 
the tried and dependable brand will usually have the advantage. A strong brand 
has to have the ability to create reliable cash flows. (41) 
Companies have to make back the cost of R&D and with the success rate in 
developing new drugs very low, the need to exploit any new products are crucial. 
By creating a brand, the success can be enhanced. Using an established branding 
practice, mainly in the non-prescription drugs area, branding can have advantages 
for the owner of the drug:  
Relationship with customers: If the pharmaceutical company builds a strong 
brand, it can go direct to the consumer. Companies that produce a “must have” 
 13 
status with health authorises, healthcare professionals and somewhat with 
patients, to create a product that any health retailer can afford not to stock the 
brand. With the rise of the internet and DTC advertising, these methods of 
exposure can help to create a relationship to create a “must-have” product. (41) 
Competitive Differentiation:  A powerful brand can surpass their competitor 
which is extremely difficult for rivals to copy. An effective branding can extend 
the life of its post-patent life, stretching out its dominance for the owner to 
maximise return on the company‟s original investment. For example, the patent to 
Zovirax (generic name: aciclovir) which is made by GlaxoSmithKline, expired 
and Bayer launched a competitor, Soothelip in December 1997. But because 
Zovirax was so well branded and the legacy was well managed, it made Bayer‟s 
entry into the market increasely tougher. (41) 
Well recognisable: a powerful brand can traverse the borders of countries and 
markets. In the pharmaceutical market, the opportunity to carry brand value over 
to the new market sectors is very attractive with the growth of the OTC sector. (2)  
For example, the drug Viagra by Pfizer. Since it went off patent, Pfizer has tried 
to sell it OTC with some success in Britain. (42) To increase its profits, Pfizer has 
used the same ingredients to create another drug called Revatio, extending the 
company‟s market. (43) 
Influence behaviour and attitudes: A powerful brand can change attitudes and 
behaviour. For example since the introduction of Prozac in the late 1980‟s, books 
have been written about the “Prozac generation” and this very successful brand 
has achieved almost iconic status and this prominence helped it to withstand 
competition in the post-patent era. (41) 
Customer loyalty: A powerful brand that can get customer loyalty can provide 
the greatest sources of wealth for a business. Some classes of drugs, such as anti-
depressants, the patients are reluctant to change, so through customer loyalty has 
more predictable cash flows. (41) 
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Creating a Brand 
Brand consultants and communications agencies prefer an advance start but the 
reality is often far from ideal. The bulk of branding work; from the establishment 
of brand values and product positioning to the choice of packaging colours only 
takes place during Phase III trials. Given that the importance of branding is 
growing, the process should generally begin earlier than it does now. (44) 
AstraZeneca implemented a rigorous branding process for all its pipeline 
products. The objective is to get all the key branding elements in place before 
Phase III trials take place. Until the beginning of Phase III trials, there will be no 
publications outside of the company, so branding the drug is not a top priority 
until Phase III. When the trial takes place, the opinion leaders who are doctors 
that will use the new drugs and eventually recommend these drug to fellow 
colleagues, get involved at this stage. The Phase III trials are significant to the 
marketing strategy and eventually the branding of the product. Doctors focus on 
the clinical aspects of the drug and at the same time exposed to the brand which 
can lead to a dedicated and constructive relationship. The marketing team in 
AstraZeneca is heavily involved in the clinical trials. When the brand profile is 
established and if a specific claim is important, the team needs studies to prove it. 
(44) 
Internal branding is another aspect in AstraZeneca. This defines all external 
communications. The brand promise is the summary of the target position, the 
expectations of where the product fits in and what makes it stand out from 
competitors. Then the brand personality is defined which are any emotions and 
characteristics associated with the product. These make up the brand essence. 
From Phase II clinical data to creating a brand essence takes up to 18 months and 
then the external communication to the public can begin. (44) 
Conclusion 
The marketing of drugs is a big business. It influences the healthcare professional 
to prescribe the drug and for the patient in persuading them to look at your 
product. 
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Pharmaceutical branding has become crucial to creating distinction from 
competitor‟s products in the mind of the patient as well as the healthcare 
professional. It‟s the eventual personality of the product in the marketplace that 
makes it a brand. 
Branding through marketing is not about adding a premium to a commodity 
product. To be more precise, it raises product awareness and boost sales by 
projecting values and emotions to healthcare professionals and consumers alike.  
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2.0 Literature Search 
2.1 Regulations  
2.1.1 United States  
The FDA (Food and Drug Administration) is responsible for protecting public 
health by assuring the safety, efficacy, and security of human and veterinary 
drugs, biological products, medical devices, the food supply, cosmetics, and 
products that emit radiation. The FDA is also responsible for advancing public 
health by helping to speed innovations that make medicines and foods more 
effective, safer, and more affordable which in turn helps the public get accurate, 
science-based information they need to use medicines to improve their health. (3) 
For the United States, the regulation of advertising is covered under Section 
502(n) of the Federal Food Drug and Cosmetic Act. This section specifies that the 
FDA is assigned the task for prescription drug branding. A drug is misbranded 
unless the manufacturer, packer, or distributor includes in all advertisements and 
other descriptive printed matter, a true statement of the established name printed 
prominently and the formula showing each ingredient of the drug to the extent 
required for labels and other information in brief summary relating to side effects, 
contraindications, and effectiveness of the drug. (4) This law emphasizes that a 
drug not to be misbranded, the generic name has to be used in the advertisement 
along with the formula with a brief summary of any risk(s) associated with the 
product must accompany each advertisement. (4) 
Another legal basis for the FDA comes from the definition of labelling in section 
201(m) of the Food Drug & Cosmetic Act. This section defines labelling as 
printed or graphic materials accompanying a drug product. The regulations go on 
to define labelling as “all labels and other written, printed, or graphic matters (1) 
upon any article or any of its containers or wrappers, or (2) accompanying such 
article”. (5) 
FDA regulations go on to define labelling to include: brochures, booklets, mailing 
pieces, detailing pieces, bulletins, calendars, price lists, letters, motion picture 
films, sound recordings, exhibits, literature and reprints, and pieces of printed 
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audio or visual matter descriptive of a drug, references published for use by 
healthcare professionals containing drug information supplied by the company are 
included in this definition. Any materials issued by or sponsored by a drug 
company about its prescription drugs are subject to the regulations. The outcome 
is that promotional materials that are not deemed to be classed as advertising are 
regulated as labelling. It was not foreseen that the FDA was going to take total 
control over all communications and marketing materials issued by the drug 
companies, but pharmaceutical companies have consented to the FDA‟s extensive 
classification of its authority. As long as the FDA enforces the regulations 
neutrally, the regulations help provide a confidence in the truthfulness of 
marketing materials. Huge collections of formal regulations, directions, informal 
policies, and enforcement actions through warning letters have developed from 
the FDA. These actions establish a system for regulating the advertising of 
prescription drugs. (2) 
The FDA has authority over any promotional activities issued by or sponsored by 
drug companies. This would include promotion to the consumer, press materials, 
detailing aids, continuing medical education, seminars, and materials for managed 
care organizations. The agency has influence over oral statements made by a 
company representative to a healthcare professional. Similar requirements exist 
for other medical products regulated by the FDA. Pharmaceutical products are 
also regulated by the FDA‟s Center for Drug Research and Evaluation (CDER), in 
which applies the same standards.  
FDA regulations that apply to the promotion of medical products are spread out in 
several sections of the Code of Federal Regulations (Title 21). Among the 
applicable sections are Part 200 and particularly Part 201 for pharmaceutical 
promotion; Part 510 for veterinary drugs; Part 601 for biological products and in 
addition, Part 801 for medical devices. (2) 
DDMAC – Division of Drug Marketing, Advertising, and Communications 
This is a division of the Center for Drug Evaluation and Research that comes 
under the umbrella of the FDA. The mission of this division is “to protect the 
public health by assuring prescription drug information is truthful balanced and 
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accurately communicated”. This is accomplished through a comprehensive 
surveillance enforcement and education program and through developing better 
communication of labelling and promotional information to healthcare 
professionals and consumers. (13) 
The DDMAC is made up of reviewers who have responsibility for reviewing 
prescription drug advertising and promotional labelling to ensure that the 
information given is not false or misleading. These reviewers provide written 
comments to pharmaceutical sponsors on proposed promotional materials to 
ensure clear and unambiguous communication of the laws and regulations 
connected with the promotion of prescription drugs. They also check complaints 
about alleged promotion violations and if found, start enforcement actions on 
promotional materials that are false or misleading. The reviewers ensure that 
regulatory requirements for products that are closely related for the labelling and 
promotional materials are consistently and equitably applied. Adding to this, the 
reviewers attend medical meetings and conventions to monitor promotional 
exhibits. Reviewers‟ liaison between the DDMAC and other divisions within the 
FDA on promotional issues that need attention. 
Monitoring 
DDMAC gives advice to the pharmaceutical industry on their proposed 
advertising and promotional labelling as specified in 21 CFR 202.1(j) (4) that any 
advertisement can be submitted to the Food and Drug Administration prior to 
publication for comment. If the advertiser has notification that the submitted 
advertisement is not in violation and later on, the FDA changes its opinion, the 
advertiser will be notified and given a reasonable time for any corrections before 
regulatory action is taken. Notification will be given in written form that a 
proposed advertisement is or is not to be considered in violation. In guidance to 
industry, the DDMAC has requested that launch campaigns be submitted 
voluntarily to DDMAC for comment before broadcasting. This is because these 
campaigns create the initial and lasting impression to prescribers in regard to the 
product‟s safety and efficacy and are the division‟s highest review priority. 
Reviewers respond within two to three weeks after the product is cleared for 
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marketing or after any labelling issues have been negotiated. Under 21 CFR 
10.85, companies may request an advisory opinion on promotional pieces before 
the company uses them. (14) 
The DDMAC has the right to monitor prescription drug promotion for compliance 
with the law. Any promotion cannot be false or misleading and always be 
presented with fair balance. The division‟s surveillance is conducted in a number 
of ways: 
Submissions from drug applicants 
Drug applicants required to submit specimens of mailing pieces and any other 
labelling that is devised for promotion of the drug product at the time of initial 
distribution and publication of the advertisement for the prescription drug. The 
DDMAC reviews the packaging to determine if they meet the requirements of the 
regulations. 
Conferences 
Staff from DDMAC attends medical professional conferences to observe 
company exhibition booths and collect promotional materials to review. Launch 
campaigns, submissions from companies and materials obtained through 
surveillance activities and complaints are assigned to the reviewer that is 
responsible for the drug or product class. (14) 
Consultation 
The DDMAC can advise on different methods of promotion: 
Direct-to-Consumer Advertising  
Any advertising that is directed towards consumers must meet the same 
requirements as promotion directed to health professionals. Drug application 
reviewers may send direct-to-consumer (DTC) advertising pieces to ensure 
consistency in applying the regulations to this type of advertising. 
Pharmacoeconomics/Managed Care 
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Consults for the pharmacoeconomics and managed care issues are sent to the 
epidemiologist in DDMAC to determine whether related claims meet the 
requirements of the regulations. Pharmacoeconomics refers to the measurement of 
the costs and effects of pharmaceuticals in terms of price, cost-effectiveness and 
other cost ratios and quality of life. 
Medical 
The reviewers work closely with medical review staff where evaluating scientific 
claims used in the promotional materials and contact the medical staff regarding 
scientific questions about products 
The full promotional review process by the DDMAC is outlined in figure 1. 
 
Figure 2.1: Promotional Material Review Process (14) 
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Launch Letter 
The reviewer performs a historical review in which he/she reviews the files for 
the products previous promotional pieces and for competing products in the same 
therapeutic class. At the end of this launch campaign review process a “launch 
letter” is sent to the applicant. This is in response to a submission. In this letter, 
the reviewer provides the applicant with comments about the proposed launch 
campaign.  
Violations/Complaints 
If the DDMAC receives a complaint about the promotion of prescription drugs or 
if a reviewer observes a violation, then the reviewer decides whether the issue 
needs to be discussed at “enforcement rounds” meetings. This is a weekly 
meeting that is devoted to discussing regulatory concerns, complaints, 
enforcement options and status of actions regarding advertising under review in 
the division.  If it is decided at the enforcement rounds meeting that an 
enforcement action is needed, there are three ways that the DDMAC can deal with 
the violation/complaint: 
Untitled Letters 
This letter concerns with promotion violations that are less serious than those 
addressed in warning letters. In such letters, there are requests that a company 
takes specific action to bring the company into compliance within a certain 
amount of time, usually ten working days. The agency has no requirement to take 
enforcement action but the letters may serve as a basis for additional regulatory 
action. 
Warning Letters 
Warning letters are written communications notifying the company that the 
DDMAC considers one or more promotional pieces or practices to be in violation 
of the law. If the violation is not corrected as requested, further enforcement 
action is taken without further notice. The company has fifteen working days to 
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respond and the warning letters are displayed at the time of issuing in the FDA‟s 
Freedom of Information Office and on their website. 
Other Enforcement Actions 
If the warning letter is not heeded other possible enforcement actions could 
include recalls, seizures, injunctions, administrative detention and criminal 
prosecution. 
2.1.2 European Regulations 
In similarity with the FDA, the European Union (EU) has the European 
Medicines Agency (EMA) which was founded in 1995. The agency is responsible 
for the scientific evaluation of applications for European marketing authorisation 
for medicinal products (centralised procedure). Under the centralised procedure, 
companies submit a single marketing authorisation application to the agency. 
Once granted by the EC, a centralised marketing authorisation is valid in all EU 
and EEA states. The key committee, Committee for Medicinal Products for 
Human Use (CHMP) issues an opinion that is almost always followed, but not 
pursued completely. The EMA is powerful, controlling about 70 percent of new 
products entering the market. However, most of the products that were permitted 
for the EU obtained their entry status onto the market through approval 
procedures at the member-state level. The EMA coordinates marketing 
authorization for the EU nations, but member states are responsible for 
enforcement. They also maintain licensing and control sales and promotional 
activities of drugs. (6) 
In contrast to the FDA, EU regulators have powers that are not available in the 
United States, which includes a ban on direct- to-consumer advertising. This is 
covered under Council Directive 89/552/EEC under Article 14 which states that 
television advertising for medicinal products and medical treatment available only 
on prescription in the member state within the jurisdiction in which the 
broadcaster falls is banned. (10) This article is extended under Directive 
2001/83/EC to other media.  But in recent times there has been an application to 
change the directive in a limited way. A directive on information to patients 
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concerning pharmaceuticals which will propose an information strategy for 
providing EU citizens with understandable good-quality objective reliable and 
non-promotional information about the benefits and the risks of medicines and 
treatments. The existing ban on direct advertising of prescription drugs will 
remain in place but the intention is to clearly distinguish between advertising and 
non-promotional information. (8) A compromise has been made between the EU 
and Europe‟s pharmaceutical companies through an independent authority that 
would examine the information provided to patients under the proposal that would 
let the industry communicate directly to consumers. (9) 
Further restrictions on advertising to the general public extend to non-prescription 
medicinal products as well. In Directive 2001/83/EC states that advertising could 
affect public health if it‟s excessive and ill-considered. The advertising of 
medicinal products to the general public, where permitted, has to satisfy certain 
essential criteria which are defined. (7) Under Article 87 (3) emphasizes that the 
sensible use of the product: “by presenting it objectively and without exaggerating 
it properties…” and “shall not be misleading”.  Article 89 sets out that all 
advertising of a medicinal product to the public should be understandable in what 
is being said and the product is clearly being acknowledged as a medicinal 
product. The brand name, if there is only one active substance, should have the 
generic name mentioned. Information on how to use the drug correctly and 
direction to read the instructions is to be included. 
Free samples of medicinal drugs for promotions are prohibited. The advertising of 
medicines to qualified people who can prescribe or supply them must have 
additional information available. This advertising is subject to strict conditions 
and monitoring under Directive 84/450/EEC. Qualified people must have access 
to “neutral objective sources of information about products available on the 
market…..” (7) 
2.1.3 Irish Regulations 
The primary Irish legislation relating to the advertising of medicinal products in 
Ireland is the Medicinal Product (Control of Advertising) Regulations 2007. The 
regulation enacted into Irish law is the Directive 2001/83/EC on the advertising of 
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medicinal products for human use and covers advertising to both health 
professionals and to the general public. 
In the regulations, advertising medicinal products includes any form of door to 
door information, canvassing activity or incentive designed to promote the 
prescription, supply, sale or consumption of medicinal products. This includes the 
advertising of medicinal products to the public and to person qualified to 
prescribe or supply them; visits by medical sales representatives to healthcare 
professionals and supply of samples. The regulations also define that the 
provision of incentives to prescribe or supply medicinal products by gifts, offers 
or promises of any benefits or bonuses, whether by using money or other 
methods. The sponsorship of promotional meetings attended by qualified 
healthcare professionals that can prescribe or supply medicinal products and 
sponsorship of scientific congresses attended by healthcare professionals and in 
particular payment of their travelling and accommodation expenses. (28) Under 
the regulations, „misleading advertising‟ is defined as any advertising including 
its presentation deceives or that it‟s likely to deceive the persons to whom it‟s 
addressing and that it affects their economic behaviour or is likely to defame the 
name of a rival company. 
Paragraph 6 (1) states that a company cannot issue an advertisement unless the 
product has a marketing authorization or a certificate of traditional use 
registration. According to paragraph 7, an advertisement cannot be released unless 
all parts of the advertisement must comply with the particulars set out in the 
summary of product characteristics and that the advertisement encourages the 
rational use of the product by presenting it objectively and without exaggerating 
its properties and is not misleading. 
Advertising of prescription-only medicinal products to the public is not allowed. 
When a medicinal product is advertised to the public, the advertisement must not 
give the impression that the product replaces a medical consultation or a surgical 
operation and cannot offer a diagnosis or suggesting a treatment by mail. An 
advertisement cannot suggest that the product is better than a competitor or does 
not have any side effects or that the effects of the product are guaranteed. Also 
 25 
prohibited is the suggestion that the health of the customer can be enhanced and 
that the health of the person could be affected by not taking the product. 
Advertisements cannot be directed at children and cannot contain celebrities to 
encourage the consumption of the product. (28) 
Form and content of advertisements 
Under the regulations, an advertisement cannot be issued unless its message is an 
advertisement and clearly states that there is a medicinal product being sold. It 
must include the name of the product; the common name of the active ingredient 
if there‟s only one main ingredient and information on the correct way of usage. 
A statement instructing the customer to read the instructions on the leaflet or 
package has to be printed. Regulations do not apply to reminder advertisements, 
once it consists of only the name of the product and advice to read the instructions 
carefully. 
Free Samples 
Samples of medicinal products are not allowed to be sold or supplied for 
promotional purposes to the public. This applies to the holder of the marketing 
authorization and to anyone that manufactures medicinal products or sells 
products by wholesale. 
Free samples can only be given to healthcare professionals and that satisfies the 
following: 
 The sample has the purpose of acquiring experience in dealing with it 
 Samples of each product is limited to six each year 
 Supplied only in response to a written request 
 Supplies of samples are control by the suppliers 
 The sample is no bigger than the smallest product on the market 
 The sample is marked “free medical sample – not for sale” 
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 Accompanied by summary of product characteristics 
 Advertisements to healthcare professionals  
An advertisement cannot be issued unless it includes abbreviated prescribing 
information: 
 Summary of the product information 
 Name of the product and a list of the active ingredients using generic names 
 Classification of the product 
 Indications of use 
 Clear statement of adverse reactions, precautions and contradictions 
 Summary of dosage and method of use 
 Name and address of the holder of marketing authorization 
Reminder Advertisements 
Reminder advertisements must contain the following: 
 Essential information of the summary of the product characteristics 
 Name of the product, trademark and generic name 
 Classification of the product 
 Name and address of the marketing authorization holder 
 Statement that further information is available 
Written material accompanying promotions 
There is a prohibition of sending or delivering to healthcare professionals of a 
product of any written material unless it has the essential information of the 
product characteristics; the classification of the product and a statement showing 
the date on which the document was drawn up or last revised.  
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Information that‟s given in written form has to be accurate, up-to-date, verifiable 
and complete. This is to enable the recipient to form his/her own opinion of the 
therapeutic value of the product. If there are any quotations, tables or other 
illustrations, these must be reproduced accurately and the precise sources of the 
information are indicated. (28) 
Medical Sales Representatives 
Under the regulations, representatives must have a summary of the product 
characteristics for each product that they promote. They must report to the Irish 
Medicines Board (IMB) any information about the use of the products with 
reference to any adverse reactions that are reported in visits. When the 
representative is promoting medicinal products to healthcare professionals, they 
cannot supply, offer or promise any gifts, financial advantage or benefit in kind 
unless it is inexpensive and relevant to the practice. The representative can offer 
hospitality at sale promotions or other events once the hospitality is reasonable in 
level and limited to the main purpose of the event.  
The holder of a marketing authorization, under regulations, has the responsibility 
to compile and collate all information gathered from the representatives or any 
other sources about the product. They also must ensure that the representatives are 
given adequate training and have knowledge to provide the information about the 
product precisely. The holder has the responsibility to make sure that the 
representatives have summaries of product characteristics for each product and 
that they send on any information relating to the product, such as adverse 
reactions. 
Sample advertising  
The holder must keep sample advertising being given out and supply, if requested 
by the IMB any advertisement or proposed advertisements. If there are any 
changes to the advertisement by the IMB, this must be complied with and 
changed immediately and conform to the regulations. If there are any corrections 
to an issued or displayed advertisement by the IMB, the marketing holder has to 
publish a corrective statement in an acceptable form.  
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2.1.4 Japanese Regulations  
Pharmaceutical Affairs Law 
The Pharmaceutical Affairs Law (Article 66 – Article 68 of Chapter 8) prohibits 
the advertising of prescription drugs aimed at the general consumer, advertising of 
the name, manufacturing method and indications of a drug before approval along 
with false or exaggerated statements.  Article 66 states that “No person shall, 
explicitly or implicitly, advertise, describe or circulate false or exaggerated 
articles in terms of the name, manufacturing methods, indications and effects or 
performance of a drug, quasi-drug, cosmetic or medical device”. (19) The law 
also forbids articles that might lead to a misunderstanding that physicians or other 
healthcare professionals that have confirmed the indications and effects or 
properties/performance of the drug, quasi-drug, cosmetic or medical device. 
Under this any articles that are written must not quote healthcare professionals 
that have not been in the testing of the drug and lead to any misunderstanding of 
the general public about the properties/benefits of the drug. Article 68-3 prohibits 
documents or diagrams that suggest criminal abortion or have obscene statements. 
Article 67 covers the restriction of advertising drugs for specific diseases. This 
article covers the advertisement of any drug, which without the supervision of a 
healthcare professional, could cause a risk to the patient. These drugs are covered 
under a government ordinance. Under the article, there are “restrictions of the 
means of advertising to the ordinary consumers other than those engaged in 
medical care and pharmaceutical affairs” (19)  
Article 68 specifies that “No person shall advertise the names, manufacturing 
methods indications and effects or performance of the drugs or medical 
devices......which are not granted certification......” The company or any person 
belonging to the company cannot advertise the drug or medical device before it 
has been approved for the Japanese market. 
Under Article 68-3 paragraph 1 encompasses the information that is given on the 
immediate containers and has to be labelled as a biological product. Under Article 
68-4 covers the information on package inserts and must draw the persons 
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attention to the properties of the biological product (19) Article 68-6 states that 
“No biological product shall, unless it does not comply with necessary standards 
established..... be retailed, rented, handed over or manufactured, imported, stored 
or exhibited for the purpose of retail, rental or hand-over”.  Under 68-7, a 
healthcare professional that deals with biological products shall provide an 
explanation to patients. This is to get the patient to understand in how to use the 
drug properly and to provide the efficacy and safety of the product. 
Japanese regulations have recently included the spread of internet advertising with 
the advertisement of unapproved drugs by persons acting as importers with the 
introduction of guidance and control of individual importers. (11) 
Under the Pharmaceutical Affairs Law, the minister of the MHLW, prefectural 
governors or others can appoint “pharmaceutical inspectors” in connection with 
the rationalization of pharmaceutical manufacture, import labelling 
advertisements or marketing. This inspection system covers falsely labelled drugs, 
drugs of poor quality, drugs that have not been approved or licensed and false or 
exaggerated advertising. (11) 
2.2 Industry Organisations 
2.2.1 United States - Pharmaceutical Research and Manufacturers of 
America (PhRMA)/Advanced Medical Technology Association (AdvaMed) 
PhRMA 
The industry in the United States has a number of organisations to represent them. 
One of these is PhRMA (Pharmaceutical Research and Manufacturers of 
America). This organisation represents research-based pharmaceutical and 
biotechnology companies. Its mission is to win advocacy for public policies that 
encourage the discovery of life-saving and life enhancing new medicines for 
patients by pharmaceutical and biotechnology research companies. To accomplish 
this mission, PhRMA is dedicated to achieving not only in the US but throughout 
the world 1) Broad patient access to safe and effective medicines through a free 
market without price controls 2) Strong intellectual property incentive and 3) 
transparent efficient regulation and a free flow of information to patients. (12) 
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Code on Interactions with Healthcare professionals 
PhRMA‟s member companies are committed to following the highest ethical 
standards and all legal requirements in their interactions with health care 
professionals. In 2009, a newly revised code was adopted, “Code on Interactions 
with Healthcare professionals”. This code addresses interactions with respect to 
marketed products and related pre-launch activities. (15) 
The PhRMA guidelines are to make certain that the “appropriate marketing of 
medicines ensures that patients have access to the products they need and that the 
products are used correctly for maximum patient benefit.” (15) These 
organisational guidelines take into account that the relationship between the 
companies and healthcare professionals are critical because it enables the 
companies to: 
 Inform the healthcare provider of the benefits and risks of the products to help 
advance appropriate patient use 
 Provide scientific and educational information 
 Obtain feedback and advice through consultation 
 Support medical research and education 
According to the guidelines, any promotional materials that are provided to 
healthcare professionals from or on behalf of a pharmaceutical company should 
be: 
 Be accurate and not misleading 
 Make claims about a product only when substantiated 
 Reflect the balance between risks and benefits 
 Be consistent with all other FDA requirements governing communications 
(15) 
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The PhRMA code states that any interactions between pharmaceutical company 
representatives and health care professionals should be focused on providing 
information on products, scientific and educational information and supporting 
medical education. In the code, it states that the company representative can take 
the chance to present information during the healthcare professionals‟ working 
day including mealtimes. The code also goes onto state that any meals provided 
are occasional and can be offered as a business courtesy to the healthcare 
professional and any member of the team attending the presentations once the 
presentation provides “scientific or educational value”. These meals must be 
limited to office or hospital locations and inclusion of the spouse of the healthcare 
professional is not appropriate. (15) 
Prohibition of Non-educational Items 
The code prohibits distribution of non-educational items such as pens, mugs and 
other reminder objects with the company logo on it to be distributed to healthcare 
professionals.  This is to ensure that no misperception that the company 
interactions with healthcare professionals are not based on informing them about 
medical and scientific issues. (15) Along with this, the pharmaceutical companies 
are prohibited from providing entertainment or recreational items for example, 
tickets for sporting events or for the theatre, any non-educational items e.g. 
artwork or music CDs. Educational items can be offered occasionally once they 
are primarily designed for the education of the patients or the healthcare 
professional in question. These cannot exceed the value of $100 and they have no 
value for the professional outside his/her work environment. Payments in cash or 
cash equivalents are prohibited unless they are payment for legitimate services. 
Product samples can be provided once in accordance with the Prescription Drug 
Marketing Act. (15) 
Support for Continuing Medical Education 
Continuing medical education (CME) helps healthcare professionals to gain 
information and insights that can contribute to the improvement of patient care 
and according to the guidelines financial support from pharmaceutical companies 
is appropriate. Such financial support for CME is intended to support education 
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on a full range of treatment options and cannot promote a particular medicine. 
This CME grant-making function should be separated from its sales and 
marketing departments. The company must ensure that it‟s a genuine educational 
program and due to the financial support does not encourage prescribing a 
particular medicine or suggesting a course of treatment. Any subsidy towards the 
healthcare professional can be viewed as an inappropriate cash gift; the money 
should be given to the CME provider in reducing the registration fee for the 
conference. Under the code there is a responsibility for the management over the 
selection of content, faculty, educational methods, materials and the venue that all 
belongs to the organisers of the conferences/meetings and organised in 
accordance with their guidelines. The company is not allowed under any 
circumstances to give advice on the running of the event. Financial support cannot 
be given toward the cost of travel, lodging or other personal expenses attending 
these events. (15) 
Consulting 
This allows companies to obtain information or advice from medical experts on 
topics such as product therapeutic areas and patients needs. This information is 
used to ensure that the medicines they produce and marketing are meeting the 
needs of patients. According to the code, the selection or retention of healthcare 
professionals as consultants should be based “on defined criteria such as general 
medical expertise and reputation or knowledge and experience regarding a 
particular therapeutic area”. (15)  Consultant arrangements are neither 
inducements nor rewards for prescribing or recommending a particular medicine 
or course of treatment. Under the code, it is satisfactory to give compensation for 
the consultant services. This does not apply for token consulting or advisory 
arrangements. (15) 
For the position not to be a token consulting arrangement all or some of the 
following factors apply: 
 Written contract 
 Legitimate need for the consulting services 
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 Criteria for selecting consultants 
 The number required is not greater than the number necessary to 
achieve the purpose 
 Retains records and make use of the consultants 
Speakers 
Pharmaceutical companies sponsor speaker programs to help educate and update 
healthcare professionals about the benefits, risks and uses of the company 
medicines. The company hires a healthcare professional to participate in this 
program. This healthcare professional is employed on his/her medical expertise 
and reputation, knowledge and experience in a certain therapeutic area and 
communication skills. As the same for consultants, the speaker cannot 
recommend one course of treatment or a particular medicine. Under the FDA 
rules, it holds companies accountable for the presentations of their speakers. So 
speaker training is an important undertaking. Compensation for this training can 
be offered but only when the participants receive extensive training on the 
company‟s drug products. (15) 
The compensation offered to the speaker in connection with a speaking 
arrangement should be based on the fair market value. The company should limit 
the total amount of annual compensation it pays to an individual healthcare 
professional in connection with all speaking arrangements. The speakers and their 
materials should clearly identify the company that‟s sponsoring the presentation 
and that the speaker is presenting the company. The company should at regular 
intervals monitor the speaker programs to ensure that it is in compliance with 
FDA regulations. (15) 
Independence and Decision Making 
A pharmaceutical company, according to the code cannot provide “grants, 
scholarships, subsidies, support, consulting contracts or educational or practice 
related items” to a healthcare provider in exchange for prescribing products or 
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commit to continue prescribing the company‟s products.  This would interfere 
with the independence of the healthcare provider prescribing practices. (15) 
Training and Conduct of Company Representatives  
These representatives contribute to the delivery of accurate, up-to-date 
information to healthcare providers about the approved products along with the 
benefits and risks of pharmaceutical treatments. These representatives are the 
primary point of contact between the companies who research, develop, 
manufacture and market medicines and the healthcare providers who prescribe 
them. They must act with the “highest degree of professionalism and integrity”. 
The company must ensure that they get training in the appropriate regulations and 
codes of practice that regulates their interaction with healthcare professionals. The 
company must ensure that they have enough knowledge of general science and 
product-specific information to provide information that is coherent with FDA 
requirements. (15) 
Direct-to-Consumer (DTC) Advertisements  
PhRMA has established guidelines for Direct-to-Consumer (DTC) advertising.  
There are two types of DTC advertising: print and television. A Direct-to-
Consumer television advertisement is a portion of television air time on broadcast 
or cable television that is bought by a company for the purpose of presenting 
information about one or more of the company‟s medicines. (16) This does not 
include sponsorship of activities. A Direct-to-Consumer print advertisement is 
space that is bought by a pharmaceutical company in a newspaper or magazine 
that are targeted to patients or consumers or in some cases, a direct mail 
communication paid for and sent out to patients or consumers for the purpose of 
presenting information about one or more of the  company‟s medicines. 
The advertisements must comply with all FDA regulations with any information 
claimed be accurate and not misleading. The advertisement should make claims 
when supported by substantial evidence and the benefits and risks should be 
balanced and consistent with FDA approved labelling. (16)Working with the 
FDA, pharmaceutical companies should responsibly to alter or discontinue a DTC 
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advertisement and voluntarily submit all new DTC television advertisements 
before releasing it for broadcast. The print advertisement should include the 
FDA‟s toll-free Med Watch phone number and website for reporting potential 
adverse events. The television and print advertisement should clearly indicate that 
what is being advertised is a prescription drug to distinguish it from non-
prescriptions products. (16) Any advertisement should promote responsible 
communications between the patient and the healthcare professional including 
health benefits and risks. If the advertisement gives the name of a product it must 
clearly state the health conditions for which the medicine is approved. (16) 
The company should get feedback from healthcare professionals and patients to 
judge the educational impact for the patient and consumers during the 
development of a campaign. There is a responsibility on the part of the 
pharmaceutical company that the advertisement must educate the general public 
about the medicine. The company must inform them about an upcoming 
advertising campaign before starting the first DTC advertising promotion.  
Actors 
Another guideline is that when the company includes actors to promote their 
products as healthcare professionals it must be stated that actors are being used. If 
an actual healthcare professional is being used, it must be stated that he/she is 
being paid for doing the advertisement. If the company decides to feature a 
celebrity, the endorsements should “accurately reflect the opinions findings 
beliefs or experience of the endorser”. Also what should be stated is whether the 
celebrity is or has been a user of the product. (16) 
Awareness 
Any advertisement should include information about other options such as diet 
and lifestyle changes where appropriate for the condition advertised. Companies 
are encouraged to promote health and disease awareness as part of the DTC 
advertising along with information where appropriate of help for the uninsured 
and underinsured.  
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Advanced Medical Technology Association (AdvaMed) 
The AdvaMed (Advanced Medical Technology Association) Code of Ethics is 
intended to address the unique interactions that occur between the 
medical/combination device companies and healthcare professionals. The code 
arises primarily from the fact that companies interact with healthcare 
professionals because of the complication and “hands on” character of medical 
technologies along with the consequence of having health care professionals 
understand how to use the technologies safely and effectively. The association 
recognizes the obligation to “facilitate ethical interactions between companies and 
those individuals or entities involved in the provision of health care services 
and/or items to patients”. (17) 
Training and Education Program 
The training and education programs include practical training sessions, 
workshops, lectures and presentations and grand rounds. Under legislation, the 
FDA mandates training and education to allow for the safe and effective use of 
certain medical technologies.  When companies are conducting training and 
education programs they should adhere to certain principles: 
 The programs and events stages should be conducted in settings that are 
conductive to the effective transmission of information. These include 
clinical educational conference or other settings e.g. hotels. In some cases 
to hold the session at the healthcare professional‟s location. 
 When there is hand on training on medical technologies, these should be 
held at training facilities medical institutions, laboratories or other 
appropriate facilities. The staff that do the training have to have the proper 
qualifications and expertise to conduct the training. 
 The company may provide the attendees with modest meals and 
refreshments in connection with the training programs. They should be 
modest in value and do not distract from the purpose of the meeting. 
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 A company can pay for reasonable travel and accommodation of the 
healthcare providers attending. This does not include guests or any other 
person who does not have an interest in the information being shared at 
the meeting. (17) 
Third Party Educational Conferences 
Companies can support these conferences in many ways but through indirect 
means. This can include conference grants, meals and refreshments, facility 
expenses and advertisements and demonstrations. A grant can be given to the 
conference sponsor to reduce the conference costs. This can be given to a training 
institution or sponsor to allow attendance by healthcare professional in training. 
Grants maybe given if the conference is primarily dedicated to promoting 
“objective scientific and educational activities” and that the institution or sponsor 
selects who is attending the conference. (17) 
Sales Promotional and Other Business Meetings 
Business meetings generally occur close to the place of business of the healthcare 
professional. Under the code, it is appropriate to pay for reasonable travel costs of 
attendees when it‟s necessary. This would include plant tours or demonstrations 
of non-portable equipment. Modest meals can be provided in such meetings. It is 
not appropriate to pay for meals travel costs or lodging of guests of the healthcare 
professionals or anybody who doesn‟t have a professional interest in the 
information. 
Consulting 
Companies may pay consultants a fair market value for performing these types of 
services once they “fulfil a legitimate business need and do not constitute an 
unlawful inducement”. Any agreement with a consulting healthcare professional 
should be written and describe all services to be provided and any consulting 
arrangement entered into must have a legitimate need for the service is identified 
in advance and documented 
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The consultant must have the required qualifications and expertise to meet the 
consulting need. Any compensation paid out should have a fair market value and 
should not be based on the volume or value of the consultant‟s past, present or 
future business. The payment for any expenses by the consultant must be 
documented and be reasonable in carrying out the duties of the consulting 
arrangement. The meetings with the consultant should be appropriate to the matter 
of the consultation e.g. clinical educational, conference or other settings. Any 
meals paid for by the company should be modest in value and has no recreation or 
entertainment with these meetings.  
Recreation/Entertainment and Gifts 
A company should not provide or pay for any entertainment, event or activity for 
any non-employee healthcare professional. Any meals that are provided should be 
in setting that is conductive to scientific educational or business discussions e.g. 
healthcare professional‟s office. A company may not provide a meal for an entire 
office staff where everyone doesn‟t attend the meeting or the company‟s 
representative is not present. A company can occasionally provide items to 
healthcare professionals that could be in the benefit of the patient or serve a 
genuine educational function. The limit on items has a market value of less than 
$100 and non-educational items are prohibited. 
Provision of Coverage, Reimbursement and Health Economics Information 
Access to medical technology could be dependent on healthcare 
professionals/patients having timely and complete coverage, reimbursement and 
health economic information. Companies may provide this information once it is 
accurate and objective. No company can interfere with a healthcare professional‟s 
independent clinical decision-making or by providing coverage compensation to 
provide free services that would eliminate an overhead belonging to a healthcare 
professionals‟ business. 
 
 
 39 
Research/Educational Grants and Charitable Donations 
A company is allowed to provide research/educational grants along with 
charitable donations but provided it is not an unlawful financial inducement. 
Objective criteria for providing grants and donations should be adopted. (17) 
Research Grants can be given to support independent medical research with 
scientific merit. The research must have well-defined objectives and milestones 
and not linked directly or indirectly to the purchase of medical technologies. 
Educational grants can be given for the purpose of the advancement of medical 
education or for the education of the public.  
Evaluation and Demonstration Products 
Any samples that are given to healthcare professionals can be given at no cost to 
allow them to assess the proper use and function of the product. Evaluation 
samples are expected to be used during patient care. The number of single 
use/multiple use products that are provided at no cost should not exceed the 
amount reasonably necessary for the evaluation of the products. For multiple use 
products terms must be set out in writing and a process in place for removal at the 
end of the evaluation period unless the healthcare professional has purchased or 
leased the products. Demonstration products are identified as not intended for 
patient use by using designations as “Sample” or “Not for human use”. (17) 
2.2.2 Europe - European Federation of Pharmaceutical Industries and 
Associations (EFPIA) 
EFPIA  
The EFPIA is the representative body of the pharmaceutical industry in Europe. 
Its members are the national industry associations of thirty pharmaceutical 
producing countries in Europe and over forty leading pharmaceutical companies. 
Its primary undertaking is “to promote the technological and economic 
development of the pharmaceutical industry in Europe and to assist in bringing to 
market medicinal products which improve human health worldwide”. (18) 
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The main focus of EFPIA is in providing accurate, fair and objective information 
about medicinal products so that rational decisions can be made as to their use. 
(18) To make sure that this is done, the EFPIA code on the promotion of 
prescription-only medicines to, and interactions with healthcare professionals was 
adopted to reflect the requirements of Council Directive 2001/83/EC (Medicinal 
Products for Human Use). The organisation wants to “ensure that pharmaceutical 
companies conduct such promotion and interaction in a truthful manner, avoiding 
deceptive practices and potential conflicts of interest with healthcare 
professionals....” (18) 
The code covers the endorsement of prescription-only medicinal products and 
interactions between healthcare professionals and pharmaceutical companies. It 
covers EFPIA member companies, subsidiaries and any companies that are 
affiliated with the member companies or subsidiaries of the affiliated companies 
if they have agreed to be bound by the EFPIA code. The code covers all methods 
of promotion including oral and written promotional activities and 
communications, journal and direct mail advertising, activities of the medical 
sales representatives, the internet and other electronic communications, audio-
visual systems such as films video recordings, data storage services and the 
provision of samples, gifts and hospitality. The code covers interactions between 
member companies and healthcare professionals in the context of research or 
contractual arrangements. 
Under the code, no product can be promoted before the company has received the 
marketing authorization to allow the sale or supply of the product. Advertising 
must be not misleading and be reliable with what is claimed about the product. 
Information on the promotional material must, when appropriate, include the 
following: 
 Essential information consistent with the summary of product characteristics 
with the date the information was generated or last revised 
 The supply classification of the product 
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 The selling price or indicative price of the various presentations/conditions for 
reimbursement by social security bodies 
When an advertisement is a reminder, the above requirements are not required 
once there is no more than the name of the medicinal product, international non-
proprietary name or the trademark. The promotion under the code has to be 
“accurate, balanced, fair, objective and sufficiently complete to enable the 
recipient to form his or her opinion of the therapeutic value of the medicinal 
product concerned”. (18) Any claims made about the product have to be capable 
of being proven and if requested by a healthcare professional must be provided. 
When the product is being promoted it has to encourage the rational use of the 
medical products in which the product must be presented “objectively and without 
exaggerating their properties”. There can be no claims that the product itself or an 
active ingredient has “special merit, quality or property” except if it can be 
validated. The word “safe” can never be used to describe a product unless there is 
proper qualification and “new” cannot be used if the product has been promoted 
for over a year. Any quotations used in the advertisement must be faithfully 
reproduced or if any modifications, mentioned and sources acknowledged.  
Distribution of Promotion 
This should be aimed at anyone who has the need or interest in the particular 
information.  Any mailing lists must be kept up-to-date. If a request is made by a 
healthcare professional to be removed from a mailing list it must be acted upon. If 
the company wants to contact healthcare professionals through for any means, is 
prohibited unless there is prior permission of the recipient. All promotion sent out 
must be transparent. Any clinical assessments, post-marketing surveillance, 
experience programmes and post-authorization studies cannot be disguised as 
advertising. These must be performed for a scientific or educational purpose. 
When a company advertises in journals, it cannot resemble independent editorial 
matter and any material sponsored by a company “must clearly indicate that it has 
been sponsored by that company” (18) 
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Events and Hospitality 
If an event is organised or sponsored by a company, it has to be held in a venue 
that is appropriate to the main purpose of the event. A company is prohibited from 
organising or sponsoring an event outside its home country unless most of the 
invitees are from outside the home country of the company. Any promotional 
information that is given out at exhibition stands must comply with the laws in the 
country in which the conference/exhibition is being held. A statement must be 
provided that indicates what countries in which the product is registered and states 
that the product is registered locally or not.  Any promotional material that 
includes prescribing information, a statement has to be included which states 
registration conditions are different internationally. 
When paying for guests to attend an event, the compensation for attending the 
event is limited to travel, meals, accommodation and the registration fees. 
Companies can only pay for professionals who are attending the event. Any 
compensation has to be “reasonable” and limited to the main purpose of the event. 
This must not go beyond what healthcare professionals would be prepared to pay 
themselves (18). Facilities that are “renowned” for their entertainment are to be 
avoided. 
Gifts 
In relation to gifts, none can be offered or supplied “as an inducement to 
recommend, prescribe, purchase supply sell or administer a medicinal product”. 
Gifts such as tickets to entertainment events are banned.  But if the company is 
promoting products to healthcare professionals, gifts can be supplied only if they 
are inexpensive and relevant to the practice of medicine or pharmacy. The gift 
must only show the name and logo of the company and or only the name of the 
medicinal product or its non-proprietary name. (18) 
Samples 
When a company provides samples it must be in limited quantity and provided for 
a limited period of time to healthcare professionals who are qualified to prescribe 
the medicinal product in order to familiarise them with the product. This can only 
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be done when the healthcare professional requests samples from the company. 
The samples must not be an inducement to recommend, prescribe, purchase, 
supply, sell or administer specific medicinal products. Companies must keep a 
record of where samples are provided to healthcare professionals and for all 
medicines handled by the company‟s representatives and each sample that is 
given out should be no bigger than the smallest product size on the market and  
marked “not for sale” or “free medical sample” and to come with a summary of 
the product characteristics. (18) 
Donations, Grants and Sponsorship 
Any donations that are given to institutions organisations or associations that 
consist of healthcare professionals which provide healthcare or that conduct 
research must only be given to support healthcare or research carried out. These 
donations must not be an inducement to sell, buy or prescribe specific medicinal 
products. Any donations that are given must be kept on record and made public. 
Donations, grants or benefits in kinds cannot be given to individual professionals. 
(18) 
Funding for healthcare professionals attending training or events must comply 
with the regional codes. Financial support for international events is covered 
under the rules of where the healthcare professional carries out his/her work rather 
where the international event is being held. 
Fees for Service and Consulting 
Contracts that are drawn up between companies, institutions organisations or 
associations that provide a service for the company are allowed once they are 
provided for the purpose of supporting healthcare or research and doesn‟t induce 
the organisations to recommend, sell or supply specific medicinal products. 
When companies hire individuals or groups for consulting positions, certain 
conditions must be adhered to. A written contract or agreement is drawn up 
describing the services that are required. The consultant(s) must have the correct 
qualifications/expertise to do the job and the number that is hired is not greater 
than the number necessary to get the job done. The company keeps records of the 
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employment and makes use of the services by the consultants. Any agreement 
with the consultant must not be an inducement to sell or supply a particular 
product. When the consultant speaks in public, there is an obligation to declare 
that the speaker is in employment with the particular company in question. (18) 
Medical Sales Representatives  
The company must ensure that any staff retained by way of contract with third 
parties and any other company representatives who call on healthcare 
professionals‟ in connection with the promotion of medicinal products are 
knowledgeable of any applicable codes and regulations. They must be trained and 
have enough scientific knowledge in order to provide accurate and precise 
information about the products they promote. Sales representatives must approach 
their duties “responsibly and ethically” and must have available the product 
characteristics for any medicinal product they promote. Any information 
including side effects must be reported to the company in the use of their 
products.  
Company Specialists 
Each company must retain on their books a scientific service in charge of 
information about each of the company‟s medicinal products and about the 
approval and supervision of non-interventional studies. This scientific service 
must include a medical doctor or a pharmacist who is responsible for the approval 
of promotional material before release. This promotional material has to be a fair 
and truthful presentation of the facts about the medicine. There must be at least 
one senior employee who is responsible for supervising the company and 
subsidiaries to ensure that the standards of the applicable code are being met. 
2.2.3 Ireland - Irish Pharmaceutical Healthcare Association (IPHA) 
Section 16 of the of the Irish regulations allows the minister to approve any code 
of practice for the purpose of providing practical guidance with respect to the 
requirements or prohibitions of the regulations. 
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The minister has approved the following Irish Pharmaceutical Health Authority 
Codes of Practice to complement the regulations: 
 The Code of Marketing Practice for the Pharmaceutical Industry 
(Pharmaceutical Code) 
 The Code of Standards of Advertising Practice for the Consumer Healthcare 
Industry. 
The Pharmaceutical Code provides guidance on the advertising and promotion of 
prescription and non-prescription medicines to doctors, dentists and pharmacists 
but not to the public. These two codes are voluntary but are highly influential that 
they have been prepared in consultation with the department of health and 
children and the Irish Medicines Board.  
Providing Information Prior to Authorisation of Medicinal Products 
The Pharmaceutical code permits provision of promotional material at scientific 
conferences or meetings in respect of a medicinal that is not the subject of an 
authorization in Ireland, once the product is authorized in at least one member 
state of the EEC once the meeting is international and that the marketing material 
clearly states that their medicinal product is not authorized in Ireland. (29) 
It is possible to publish information on unauthorized medicines that is purely 
factual and not promotional. Press releases are prohibited before authorization and 
any information sent to healthcare professionals is classed as promotional and 
therefore prohibited. 
Advertisements to Health Professionals 
The pharmaceutical code provides that where the purpose of any promotional 
material is to provide healthcare professionals with abbreviated prescribing 
information (API) to enable them to decide to prescribe or not a particular 
product, the following information is given: 
 A quantitative list of active ingredients contained in each unit of dose 
 Recommended dosage, method or use and administration 
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 The side effects, precautions and contradictions of the preparation in the 
recommended dosage 
 A statement that additional information is available on request (29) 
Any mailings or journal advertisements cannot resemble editorial matter and 
cannot imitate other company‟s devices layout or slogans. Advertisements cannot 
use names or photographs of healthcare professionals in a leading manner. 
Comparisons of products must not mislead and other similar products cannot be 
disparaged directly or indirectly. (29) 
 
Figure 2.2 Example of API from an advertisement aimed at doctors 
Gifts  
There is a prohibition in the supply, offer or promise to a health professional of 
any gifts, financial advantages or any benefits in kind unless they are inexpensive 
and relevant to the practice of the healthcare professional. If the gift or a 
promotional aid contains other information than just the name of the product, 
name and logo of the company, these gifts are covered under the rules on 
advertisements. Inducements by way of financial donations to institutions or 
individuals to buy the company‟s product (s) are prohibited. (29) 
The pharmaceutical code emphasizes the need for a moderation in corporate 
hospitality and once that the scale and costs of the hospitality given does not 
exceed the level in which the recipients would normally pay themselves. 
Sponsorship is based on the scale of the scientific meetings/conferences being 
held. Direct payment to healthcare professionals attending is prohibited while 
paying the speaker is fine. (29) 
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Samples  
In the code, the following rules supplement the regulations on the distribution of 
samples: 
 Samples distributed my medical representatives must be handed to the 
healthcare professional directly or an authorized person 
 Samples sent by post must be packed so it is secure against opening by 
children 
 Distribution of samples in hospitals must comply with hospital regulations 
(29) 
2.2.4 Japan - Japan Pharmaceutical Manufacturers Association (JPMA) 
The JPMA has set out a standard of conduct that must be adhered to by any 
member pharmaceutical company when conducting promotional tasks of 
prescription drugs. This is called the JPMA Promotion Code for Prescription 
Drugs. 
As part of this Code, the member companies are responsible for all promotional 
activities conducted by the company itself along with its medical representatives. 
The companies are required to establish an internal system to carry out the 
appropriate promotional activities. (20) Any subsidiary company, holding 
company or business partners who conduct sales and promotion in Japan must 
adhere to the JPMA Promotion Code. 
To comply with the Code the member company must appoint qualified employees 
as medical representatives along with the introduction of education and training 
programmes. Any evaluation or remuneration package does not encourage 
unethical acts by the medical representatives. The company must provide up-to-
date information such as indications dosage etc and take care that the 
representatives when providing the information about the product do not move 
away from the approved items for the particular drug in question. In-house 
systems are established to comply with all relevant law and regulations. (20) 
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Medical representatives go out representing their companies and must perform the 
following in an honest manner: 
 Gain knowledge of the drugs along with medical and pharmaceutical 
knowledge and gain the abilities to present the information gathered 
correctly 
 Conduct the promotion of the drug according to the rules and regulation 
established by their companies 
 Provide fair and balanced information 
 Collection and dissemination of drug information as quick as possible 
 Not to slander or defame competitors or competitors drugs 
 Abide by rules imposed by a medical institution and the laws and 
regulations 
Promotional Materials 
Brochures, advertisements in medical journals, websites aimed at healthcare 
professionals, AV materials and other promotional materials are important media 
for giving out of drug information. This promotional material is covered under the 
Pharmaceutical Affairs Law and self regulations for the industry. The information 
that is given must be “correct, fair and objective” and based on the scientific data. 
Statements of the dosage, indications and administrations cannot digress from the 
accepted items. The efficacy and safety of the drug must be accurate and not 
misleading and examples of this would be “there are few adverse reactions”. Any 
comparisons with other drugs must be based on scientific data and the generic 
name is used. Competitors making the same drug cannot be slandered or defamed. 
Any “extraordinary” data cannot be presented in a way that it is a universal fact 
along with no misleading or indecent photos.  
When the advertisement is mainly promoting the name of a drug, the 
advertisement includes the brand name, therapeutic category, regulatory 
classification, generic name and the status of the drug price listing. A contact 
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name and address must be included for more detailed information. Each member 
company appoints a management representative for promotional materials and 
advertisings along with the establishment an auditing system so that only 
approved material is used. If post-marketing safety and post-marketing 
surveillance surveys are being conducted, these should not be used as a sales 
promotion tool. 
Supply of samples 
Samples are given to show the physical appearance of drugs, to evaluate and 
confirm for the healthcare professional the quality, efficacy, safety and any other 
claims that are made by the company. The supply of samples should be given in 
the minimum quantity necessary along with the related drug information. 
Seminars and Study Meetings 
Seminars organised by the member companies about their drugs are to be 
“academic events where scientific information is supplied”. These must be held in 
an appropriate venue conducive to the purpose. Any drinks and food provided 
must not be extravagant and if there is any social-gathering event or gift it cannot 
be excessive.  
Payments in cash or cash equivalents are limited to travel, transportation and 
accommodation expenses and the remuneration for the lecturer when holding a 
seminar. Any partners or guests of the invited healthcare professional cannot 
participate in the social gathering and cannot receive travel expenses.  
Gifts and provision of cash 
Any gifts given must not influence the use of the drugs and the gift must be in 
good taste. Cash must not be given that directly or indirectly influences the 
healthcare professional or institution to use the drugs. 
Promotional activities outside Japan 
Any information given to foreign healthcare professionals must be internationally 
consistent and in accordance with the laws and regulations and promotion code 
 50 
that are applicable in the applicable countries. Any subsidiary company of a 
member company conducting promotional activities, the member company must 
ensure that the subsidiary company adheres to the promotion code established by 
the national organisation of pharmaceutical companies of that particular country. 
Overseas licensees and agents are covered under the promotion code of the 
country in question. When promotion is aimed at Japanese healthcare 
professionals, when overseas, member companies are covered under the JPMA 
Promotion Code. If the promotion is directed to foreign healthcare professionals 
in Japan, it is covered under the promotion code established by the national 
organisation of pharmaceutical companies of the country in question. 
2.3 Summary 
There are commonalties between the regulations from each market described 
above. All the regulations cover all parts of marketing medicinal products, from 
advertisements to patients and healthcare professionals, labelling of the 
medications including Patient Information Leaflets (PIL) and Summary of 
Product Characteristics (SPC) medical representatives, the prohibition of non-
educational gifts, the funding and holding of conferences and the provision of 
samples. The regulations also prohibit excessive and ill-considered 
advertisements that could affect public health. Three out of the four markets 
reviewed (Europe, Japan and Ireland) prohibit direct advertising of prescription 
drugs to the general public while the US allows Direct-to-Consumer (DTC) 
advertising of prescription drugs to the public. In the US, a division of the FDA, 
the DDMAC (Division of Drug Marketing, Advertising and Communications) 
enforces the regulations. In Europe, the EMA (European Medicines Agency), in 
Ireland, the IMB (Irish Medicines Board) and in Japan MHLW, (The Ministry of 
Health, Labour and Welfare) enforces the regulations in each respective market. 
Many pharmaceutical organisations have guidelines that help companies follow 
and clarify the regulations. In the US, there are two organisations; PhRMA that 
deals with research based pharmaceutical and biotechnology companies. Another 
American organisation, AdvaMed deals with medical device companies. The 
Code published by PhRMA deals with promotional activities towards Healthcare 
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Professionals, including interactions with representatives and training of 
representatives, advertisements, prohibition of non-educational items, medical 
education of the HCP and DTC advertising. The AdvaMed code of ethics 
addresses the interactions between medical/combination device companies and 
HCP.  This encompasses training and education programs, funding of conferences 
and meetings, gifts, donations to charities and provision of demonstration 
products. 
In Europe and Ireland there are organisations that produce guidelines. In Europe, 
there is the EFPIA and in Ireland, the IPHA. Each set of codes covers the 
endorsement of prescription-only medicinal products and interactions between 
HCP and the pharmaceutical companies. Each code covers advertisements, pre-
marketing authorisation promotion, distribution of promotion, events and 
hospitality, gifts to healthcare professionals, samples, consultants and medical 
representatives. 
In Japan, the JPMA has set out a standard of conduct that must be adhered to by 
the member companies.  In this code, promotional activities conducted by the 
company itself inside and outside of Japan and any subsidiary companies, medical 
representatives, education and training programs, information in promotional 
materials, samples, conferences, prohibition of gifts are covered.  
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3. 0 Ethics of marketing pharmaceutical products  
3.1 Introduction 
The ethics involved with pharmaceutical sales and marketing is a matter of system 
compliance, responsibility and culture (organisational ethics). (31) The ethics is 
based on the legal requirements obligatory by law and the guidelines published by 
the regulatory boards. The law however, should be seen as a minimum standard 
and a higher ethical standard is expected from companies. Ethical behaviour must 
be used when developing the marketing and sales strategies aimed at the public 
and the healthcare professionals. The ethics within pharmaceutical sales has 
become a matter of public interest in recent times and the moral conduct of the 
major pharmaceutical companies and the industry as a whole has been examined 
for unethical behaviour within its sales and marketing practices. 
When the profit motive and human good are allied, it‟s a win-win situation. 
Pharmaceutical companies have developed and marketed medications that have 
transformed the lives of millions of patients. But the interests of the 
pharmaceutical industry and the medical profession are opposite. The practices of 
healthcare professionals and the pharmaceutical industry have different objectives 
and submit by different ethics. “Big Pharma” is a business that is governed by 
selling products and making money. The healthcare profession has an aim to 
provide the highest care to patients using whatever medication that is available. 
Healthcare professionals are often influenced by the pharmaceutical companies in 
a number of ways through gifts and visits by pharmaceutical representatives. 
These influences along with Direct-to-Consumer (DTC) advertising puts pressure 
from the patients, on the healthcare professional to prescribe a particular 
company‟s drug.  
In the four markets investigated in the first chapter, there are guidelines for 
pharmaceutical companies to follow. In the United States, these guidelines have 
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been published by AdvaMed and PhRMA. The same goes for Europe; the EFPIA 
produces a code of practice for member companies based on Council Directive 
2001/83/EC. In Japan, the Japan Pharmaceutical Manufacturers Association 
(JPMA) produced a Promotion Code for Prescription Drugs and in Ireland, the 
Irish Pharmaceutical Healthcare Association have a marketing code called “The 
Code of Marketing Practice for the Pharmaceutical Industry”.  The common 
theme among these codes is that pharmaceutical companies must have an ethical 
stance when they are dealing with healthcare professionals and “conduct such 
promotion and interaction in truthful manner, avoiding deceptive practices and 
potential conflicts of interests with healthcare professionals and in compliance 
with applicable laws and regulations”. (18)  
This ethical stance is summarized in the JPMA Promotion Code for Prescription 
Drugs: “Because pharmaceuticals by their nature have a profound impact on 
human lives, the pharmaceutical industry must always pay the highest respect to 
the dignity of human life, maintain good disciple with a spirit of modesty toward 
science and respond to the expectations of society” (20) 
3.2 Recent Examples of Misleading Marketing Practices  
In September 2009, Pfizer was fined US$2.9 billion dollars for deceitful 
marketing practices. This was done because the company was promoting 
medicines for unapproved uses or “off-label uses”. Pfizer deliberately encouraged 
doctors to prescribe four medicines to treat symptoms the drugs were not 
approved by the FDA to treat. The settlement also settles allegations that Pfizer 
induced doctors to promote these "off-label" uses by paying for their meals and 
subsidizing their travel. This is the third settlement that Pfizer has signed a 
“corporate integrity” agreement. (21) 
This is just an example of the deceitful and underhanded marketing practices that 
has occurred. This wrongdoing was done due to the fact that it takes 
approximately US$1 billion to develop and test a new drug. In recovering their 
spending, the companies want healthcare professionals to subscribe their drugs as 
widely as possible. (22) Another example is that of Johnson & Johnson illegally 
and effectively promoted Propulsid off-label for children despite internal 
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company documents raising safety concerns. (31) The side effects of this drug 
include serious cardiac arrhythmias including ventricular tachycardia, ventricular 
fibrillations have been reported in patients taking Propulid (generic name: 
cisapride). This product is no longer available in the United States (32) 
Other companies have gotten in trouble over off-sales promotion and withholding 
of critical information. In 2004, the drug Vioxx, a drug produced by the Merck & 
Co. pharmaceutical company, was withdrawn from the market. Merck voluntarily 
withdrew the product due to grave concerns about the cardiovascular side effects. 
Allegedly the company knew that the drug could increase the chances of heart 
attacks and strokes from 2000 and has been accused of engineering study results 
to minimize the risk. More than 6,000 lawsuits have been filed against the 
company in the United States by people or their families who claim they suffered 
heart attacks as a result of the drug.  (25) 
Also in 2004, a lawsuit against GlaxoSmithKline (GSK) was initiated, for 
withholding negative information on their drug Paxil (Paroxetine). Paxil is 
an antidepressant used for children and adolescents. GlaxoSmithKline agreed to a 
settlement, which involved the release of post summaries of all clinical trial 
results to be published on its corporate website for all approved products. (27) 
The case occurred after a confidential GSK memo leaked to media documented a 
1998 clinical trial that concluded paroxetine had no beneficial effect in the 
treatment of adolescents. The author of the report recommended GSK “effectively 
manage the dissemination of these data in order to minimize any potential 
negative commercial impact.”  Sales for Paxil totalled nearly $4.97 billion 
worldwide in 2003. (27) 
AstraZeneca faced a class action lawsuit alleging that it was misleading in its 
promotion of its top-selling ulcer treatment Nexium. The lawsuit was brought on 
behalf of trade union healthcare providers in New York who paid for the drug on 
behalf of their members. It demanded the return of profits made on Nexium, 
which had sales of US$3.3bn. It claimed that Nexium is no more effective than 
Prilosec, AstraZeneca's older ulcer drug, which is significantly cheaper because it 
is no longer protected from competition by patent. (26) 
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Gifts 
Gifts that are given by the pharmaceutical industry to healthcare professionals are 
controversial. Approximately, US$11billion is spent on promotion and marketing 
each year towards doctors. (23)  
GlaxoSmithKline (GSK) was investigated by German and Italian authorities for 
alleged corruption of doctors - at least 1,600 in Germany and more than 4,000 in 
Italy, where illegal gifts were handed out, and totalling €228m from 1999 to 2002. 
GSK has since established marketing codes for all employees. All new staff has to 
pass an assessment on the code of practice. The report that was published in 2004 
indicated that 87 employees were fired or have agreed to leave the company 
voluntarily as a result of the breaches of the codes and sanctions, such as written 
warnings were imposed in 109 breaches. (25) 
Allegations were made against AstraZeneca for its use of inappropriate gifts and 
promotions. It was alleged that a promotional event for the drug Crestor was held 
by AstraZeneca in the French Riviera and invited physicians to attend along with 
payment for their hotel, flights and other promotional activities which included 
tickets to musical performances. AstraZeneca says that all employees must now 
pass an exam on its code of conduct. (25)  
Pharmaceutical Representatives 
According to an analysis of studies conducted to find out the effect of the 
interaction between the medical profession and the pharmaceutical industry, 
physician interactions with pharmaceutical representatives were generally 
endorsed and began in medical school and continued at a rate of about four times 
per month. Meetings with pharmaceutical representatives correlated with requests 
by physicians to add the drugs to the hospital formulary and there was a change in 
prescribing practice of the doctor. (24) 
Overall, residents and physicians have the same attitude towards representatives. 
They believed that the representatives provide accurate information about the 
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drugs that they promote. They also believe that representatives could provide 
accurate information on established or alternative drugs. On the other hand, most 
believe that representatives prioritize the product promotion above the welfare of 
the patient and use unethical practices to do this. (24) 
In the United States, as soon as a student enters medical school, the influence of 
drug companies is evident. Free lunches, pizza, medical manuals, journal 
subscriptions, pens, reflex hammers, penlights, CDs, paperweights, clocks, 
notepads, anatomic models, and mugs, to mention just a few, are gifts given to the 
student doctor. The custom of seeing the drug representatives, listening to their 
guidance, accepting their gifts becomes a part of everyday medical practice. The 
sales representatives are attractive, approaching, and likeable. From an early stage 
in the doctors‟ career, the pharmaceutical companies have an influence on the 
medical student. 
Gift-giving invokes the “reciprocity rule”, which creates a feeling of gratitude in 
the recipient together with the desire to repay the favour in some way. Awareness 
of this commitment underlies the reluctance to accept gifts from those we would 
prefer not to be indebted to, or when we do not know what is expected in return. 
With gift-giving to healthcare professionals, the obligation is to prescribe this 
company‟s drugs rather than any other alternatives. Because medical students do 
not have the authority to prescribe, they regard themselves as being free from 
mutual obligations to gift-giving from pharmaceutical companies. This leaves the 
students with two main potentials: either they are truly getting something for 
nothing, or they are becoming indebted to the pharmaceutical industry, 
consciously or subconsciously. (33) 
To counteract this, many student associations request that their student take a 
pledge not to accept gifts. Such an example of a pledge is the American Medical 
Student Association‟s PharmFree Medical Student Pledge: 
I, _____________, am committed to the practice of medicine in the best interests 
of patients and to the pursuit of an education that is based on the best available 
evidence, rather than on advertising or promotion. 
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I, therefore, pledge to accept no money, gifts, or hospitality from the 
pharmaceutical industry; to seek unbiased sources of information and not rely on 
information disseminated by drug companies; and to avoid conflicts of interest in 
my medical education and practice. (34) 
In this way, students have pledged to avoid gifts of any sort and to get impartial 
information and not to fall into the trap of accepting gifts and letting 
pharmaceutical companies have influence over their future prescribing habits. 
3.3 Conclusion  
Pharmaceutical companies have to sell their products. They are in the business of 
making a profit from their research and development. There has been increasing 
controversy surrounding pharmaceutical marketing and influence the company 
exerts. As seen from the examples above, sometimes they can cross a line and 
threaten the health of the population. This has involved selling their products off-
label and influencing doctors and other health professionals through drug 
representatives, including the constant provision of marketing gifts i.e. pens, 
clocks, notepads. Also this unethical marketing is done through widespread 
advertising in journals and magazine aimed at healthcare professionals. The 
sponsoring of healthcare professionals to attend conferences and through funding 
of student doctors in medical school has an influence on the company‟s sales. The 
sponsoring of independent healthcare organizations and health promotion 
campaigns to increase awareness are other methods in which the company can 
market their products directly and indirectly. These marketing techniques increase 
the pressure on the healthcare professional to prescribe the drug with the cost of 
the drug to the healthcare system and eventually the ordinary patient. 
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4.0 Marketing Case Studies 
4.1 Introduction 
In this chapter, I am going to discuss two different products, Claritin (Clarityn) 
and Lipitor.  I am going to discuss their different marketing methods, how they 
built up their market share and how the companies made the products success 
through effective branding. 
4.2 Case Study 1: Claritin (Clarityn in Europe) 
Background 
The Schering-Plough company became a drug industry success due to the 
bestselling drug Claritin, anti-histamine. Spending more to advertise one pill than 
any other drug company, Schering-Plough made Claritin become one of the most 
popular allergy products and one of the most successful companies of the 1990s. 
(35) 
Claritin is an antihistamine that reduces the natural chemical histamine in the 
body. Histamine can produce symptoms of sneezing, itching, watery eyes, and 
runny nose. Claritin is used to treat the symptoms of seasonal allergies, such as 
sneezing, watery eyes, and runny nose and itching of the nose and throat. Claritin 
is also used to treat skin hives and itching in people with chronic skin reactions. 
(36)  What made Claritin prominent in the market was the non-drowsy formula. 
This was an advantage due to the fact that other competitor‟s products made 
people drowsy and that people with allergies who took Claritin could get on with 
life, which the company based their marketing campaign on. 
Claritin had a long approval process by the FDA - it was patented in 1981 but was 
not approved until 1993. This was due to the scientific controversy about whether 
it was any better than a placebo at the low doses necessary to prevent drowsiness. 
The 17-year patent should have expired in 1998 but was extended by a total of 
four years and four months of exclusivity. This was worth billions in sales. (37) 
Due to the massive advertising campaigns, Schering-Plough spent US$56.5 
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million on direct-to-consumer (DTC) advertising in the first six months of 2001 
and achieved sales of US$2.7 billion. This was due to the advantage of having a 
non-drowsy formulation. 
Claritin went on OTC sale in the US on December 10
th
 2002.  
Advertising campaigns 
Schering-plough tried another approach to advertising Claritin. Instead of dry 
statistics, it had humorous TV commercials that treated the annual allergy and hay 
fever as the annoyance that it is. In the pharmacies, it‟s packaging, with its blue 
sky and drifting clouds (Image 1), in Europe; Clarityn has a blue box with a 
pollen motif (Image 2) that stands out among the competitors.  
 
 
                               Figure 4.1: USA/Canada packaging for Claritin (38) 
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                          Figure 4.2: European packaging for Clarityn (39) 
The television commercials in the US (DTC and OTC advertising) and in Europe 
when it was an OTC drug used an unconventional approach in selling the product 
with a strong and distinctive message; along with in-store promotions helped 
Schering-Plough to capture a share of the allergies market. 
When the FDA in 1997 reduced the regulations making it easier for 
pharmaceutical companies to sell their prescription products to consumers, 
Schering-Plough jumped at this opportunity, revolutionising pharmaceutical 
marketing in the process. The company started aggressive DTC advertising. The 
Claritin advertisements that were colourful and everywhere, pressed allergy 
sufferers to ask their doctors for the pill. (1) 
Websites  
The internet is a powerful tool in advertising and Schering-Plough has made full 
use of websites especially dedicated to advertising Claritin/Clarityn, giving advice 
on allergies and the different products available.  
US Website (accessed 3
rd
 April 2010) http://www.claritin.com/ 
When you open the website, the first thing you see is advertisements (Image 4.1). 
There is a flash video that automatically goes through four advertisements. 
Underneath this video, there are smaller visual advertisements, each a link to a 
separate page. One link leads you to a competition that is associated with a 
famous person in America. The second one leads you to another section that is 
advertising another version of the Claritin product. The final link leads you to 
coupons that you can print and cut yourself.  
At the top of the page, there are links that lead you to separate pages providing 
information about allergies, about managing your allergies, a link to the full range 
of products in the Claritin range, a link to a page that provides you information 
about kids and allergies and the final one is leads to the coupon page as described 
before. 
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At the very top, there is a link for healthcare professionals that leads to a separate 
page aimed at the healthcare professionals. This page provides frequently asked 
questions, a link to a study entitled Cognitive Effects of Loratadine: Effects on 
Allergy Response, which proves that Claritin works for allergy sufferers. In this 
section of the website, there is a section that is aimed at healthcare professionals 
and parents through a children‟s books entitled “Casey and the School Day 
Sneezes” to try and help children understand allergies. This book is sponsored by 
the makers of Children‟s Claritin allergy products. 
 
                              Image 4.1: Opening page for the US website for Claritin 
European Website (accessed 3
rd
 April 2010) 
http://www.claritynallergy.co.uk/ 
The website opens with a flash video in which it shows the different situations 
that allergy sufferers can get hay fever. Beside each of these situations, there is an 
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information link where, if you move your cursor over it will bring up a box 
providing information or facts about allergies.  Beside the people in the flash 
video, there is links to their profile stories about how allergies affect their life in 
different ways and how Clarityn helps them get on with life.  
In the video, there is a plane flying across the sky, with a banner, when clicked 
on, will open a box listing the Clarityn range and where to buy the tablets. At the 
top of the page there are links to other pages. The first link opens a page, where 
you click a few boxes, can pick out an appropriate product to reduce your 
symptoms. The next one opens the products page, the same one as the banner in 
the flash video. The next link leads to a page that you can find out what allergies 
are and the different sources of the allergies. The subsequent one opens a page 
with the profiles of different people suffering from allergies from different 
sources, the same as the flash video. Another one opens a “Did You Know?” page 
that provides answers for frequently asked questions. The last link leads to a form 
page that you fill in and send an email to friends and family with allergies to 
encourage them to visit the website. 
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Image 4.2: Opening homepage for UK website 
TV Commercials 
Analysis of Claritin Television Commercial, USA, 1996 
This was before it became an OTC drug. 
It starts off with dramatic music and at the same time, a tablet with run rays 
coming towards the viewer on a clear blue sky background. It then morphs into a 
clock with the voices repeating “Claritin, it‟s time, it‟s time… it‟s time….. don‟t 
wait another minute of Claritin… I‟ll ask my doctor”. With constant reminding, 
the name of the product is mentioned and encourages the viewer to go and see 
their doctor to get Claritin. 
Then the clock morphs into a smiling woman. This enforces the main idea that if 
you take Claritin you can get relieve and be this happy without your allergies.  
The next scene is a surreal doctor‟s waiting room with a nurse entering and then 
in the next scene a man entering. At this stage of the commercial, the voice-overs 
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have enthusiasm about seeing the doctor: Woman: “Claritin… I‟ll ask my doctor” 
Man: “It‟s time to see your doctor”. The male voice-over goes onto say:  “At last, 
a clear day is here” 
At this stage the voice-overs are encouraging the customer to find out more about 
Claritin: 
Woman: I want to know more about Claritin 
Man: Yes, ask your doctor about a trial of Claritin 
When the open door appears the man is offering a five dollar coupon towards a 
prescription for Claritin and free information and encourages the customer (Image 
5) to use the phone number. 
Analysis 
An overall analysis of this commercial is that it keeps repeating the name of the 
product which gets it into the subconscious of the viewer; that when you get to 
use this product your life will be heaven and the sun will shine and the customer 
won‟t have to worry about their allergies and get on with life. The surreal doctor‟s 
waiting room makes it looks like it‟s a pleasure to go to the doctor and ask for 
Claritin. It portrays a positive, bright spin about Claritin. 
 
                     Image 4.3: The final frame of the US TV Advertisement  
Analysis of Clarityn Television Commercial, UK, 1998 
 65 
This commercial starts off with a smiling face of a man on a green background 
accompanied by instrumental music. Then flowers are seen which represents the 
start of the allergy season and you get to see the face about to sneeze.  
As the commercial goes on the background turns from a dark green to a light 
green and eventually into red. This colour change represents the worsening 
allergies, sneezing and runny nose.  
After the hanky comes in and wipes the nose of the man, a box of Clarityn flies in 
and surprises the man and everything gets back to normal. While this is going on, 
a voice over comes in quoting: “This summer don‟t suffer from hay-fever, take 
Clarityn allergy and get back to normal fast. One small tablet can relieve all your 
symptoms and gives you twenty-four hour relieve without making you drowsy”.  
The final frame has the box of Clarityn with the tag line: “Gets you back to 
normal – fast”.  
This commercial, in a simple way, emphasizes the effectiveness of Clarityn in a 
humorous way. At 29 seconds the commercial has to get the point across in a 
quick, bright attracting way. The use of colour is interesting; the bright green is 
for nature without allergies, the darker green is the onset of allergies while the red 
background represents the onslaught of the allergies. When the man is cured, the 
background is blue representing Clarityn. 
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(a)
 (b) 
Image 4.4 (a) and (b) Still frames from the European television advertisement for Clarityn  
4.2 Case Study 2: Lipitor 
Background 
Lipitor (generic name: Atorvastatin) is a type of cholesterol-lowering medicine 
called a statin. Statins block an enzyme in the liver that the body uses to make 
cholesterol. When less cholesterol is made, the liver uses more of it from the 
blood and results in lower levels of cholesterol. Lipitor reduces low-density 
lipoprotein (LDL) cholesterol and total cholesterol in the blood. Lowering 
cholesterol can help prevent heart disease and hardening of the arteries, conditions 
that can lead to heart attack, stroke, and vascular disease. (45) 
Since its launch in 1997, it has generated more than US$80bn in sales for Pfizer, 
far outstripping all other blockbusters, including Viagra. By 2004, Pfizer could 
say that Lipitor had become the world‟s first “mega-blockbuster”, generating 
annual revenues of more than US$10bn and in 2008, exceeded US$12bn. (47) 
The patent for Lipitor is to expire in June 2011. 
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Website 
US website accessed (3
rd
 May 2010) http://www.lipitor.com/index.aspx 
When the homepage opens, a flash graphic appears. In this graphic there are 
boxes slowly moving from right to left that you can click on. Some of the boxes 
link to side effects, case-studies of current users and research done about Lipitor. 
Other boxes contain information on exercise, diet and risk factors of having a 
heart attack and what is cholesterol? On the left of the flash graphic, there are 
three stationary boxes entitled “A Lipitor Heart”, “Cholesterol Basics” and 
“Living Healthy” when clicked on will bring the viewer to a particular box within 
the graphic associated with each title.  
Above this graphic there are equivalent links entitled:  
About Lipitor, About Cholesterol and Heart Disease, Assess Your Risk 
Personal Stories, For Lipitor Patients, Healthy Lifestyle Tools and Resources 
These links have a drop down menu associated with links to other webpages. 
Above these there are further links that open documents to give Patient 
Information and Physician Prescribing Information. A link opens a separate 
webpage containing Important Safety Information. 
Further down the webpage there is a paragraph entitled “If you have high 
Cholesterol” giving information on high cholesterol and on Lipitor itself. There is 
a suggestion of changing the viewers eating habits and exercising. 
At the end of the page there is a description of what Lipitor does and important 
Safety Information. There is a disclaimer at the very end of the page, saying that 
the website is not to replace discussions with the healthcare professional and any 
decisions must be made with one. Beside this information there are boxes entitled: 
“talk to your doctor about cholesterol”, “start the 12-week guide to managing 
cholesterol” and “get money saving offers and save on Lipitor”. 
It is claimed that the website is only for residents of the US and that labelling 
maybe different in other countries. 
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Image 4.5 Opening page for the Lipitor website 
Television Commercial 
Lipitor television commercial, 2008 
This commercial starts off in black and white with “John E”, a user of Lipitor 
talking about his experience of having a heart attack: 
“talk about a wakeup call – I had a heart attack at fifty-seven. My doctor told me 
that I should have been doing more about my high cholesterol……what was I 
thinking? But now I trust my heart to Lipitor. While he is talking, on the screen 
below him, there are warnings about cholesterol: “High cholesterol can clog 
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arteries and lead to heart attack or stroke”. The name of Lipitor is constantly in 
the right hand corner throughout the commercial. 
After this, it a colour sequence starts and the viewer sees that John E. is at a lake 
going to go for a cycle and a voiceover comes in saying: “When diet and exercise 
is not enough, adding Lipitor may help unlike other cholesterol lowering 
medications. Lipitor is FDA approved to reduce the risk of heart attack, stroke 
and certain types of heart surgeries or if you have several common risk factors or 
heart disease”. When the voiceover is saying this, the sentence “Lipitor is FDA 
approved to reduce the risk of heart attack and stroke” comes up on the screen. 
When this is up on the screen, a sentence comes up below: Common risk factors 
include family history, high blood pressure, low good cholesterol, age and 
smoking. The voiceover goes onto say: “Lipitor has been extensively studies with 
over 16 years of research. Lipitor is not for everyone including people with liver 
problems, women who are nursing, pregnant or may become pregnant. You need 
simple blood tests to check for liver problems. Tell your doctor if you are taking 
other medications or if you have any muscle pain or weakness. This may be the 
sign of a rare but serious side effect”. When the voiceover is talking the viewer 
sees John E. cycling with people and enjoying life. At the end of this section, he is 
seen walking with his partner looking at the sunset. A helpline telephone number 
and website address comes up at the bottom of the screen. 
Then it goes to black and white and John E. states: I learnt the hard way… but 
you may be able to do something. There is a statement at the bottom of the screen 
saying that Lipitor is one of many treatments. Then it goes to the voiceover: “have 
a heart to heart with your doctor about your risk and about Lipitor.” A 
promotional logo is shown on the screen at this stage.  
Analysis of Television Commercial 
John E. is talking for the first fifteen seconds of the advertisement about his 
experience of having a heart attack. This is filmed in black and white, to make it 
seem more serious to the viewer. The next section is filmed in colour, with John 
E. going for a bike ride by a lake. This gives the impression that he is now 
enjoying life and doesn‟t have to worry about his cholesterol levels and having 
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another heart attack. At the end of the colour section, he is seen walking with his 
partner, looking at the sunset. This enforces that he did something about his 
cholesterol after his heart attack by taking Lipitor and so he doesn‟t have to worry 
now. All this time, the voiceover is explaining about Lipitor, what it is used for, 
the side effects and how good the drug is due to the research performed for 
sixteen years and its FDA approved. 
Between John E. and the voiceover, they both encourage the viewer to learn from 
John E.‟s mistake and go to the doctor to get tested and ask for Lipitor. The name 
of the drug is constantly repeated and shown throughout the advertisement. This 
is to emphasise the drug and get it into the subconscious of the viewer. It tries to 
scare the viewer into going to the doctor before they have a serious problem. The 
ads devote 15 seconds to Lipitor's side effects and 45 seconds to benefits. 
 (a) 
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 (b) 
 
Image 4.6 (a) (b) (c) three frames from Lipitor television commercial, US 2008 
4.3 Overall Analysis 
 
There are some extreme differences in marketing prescription and non-
prescription drugs. The Claritin/Clarityn websites are fun, informative and user 
friendly. They are brightly coloured and attractive to the eye. On the other hand, 
the Lipitor website is informative and somewhat user friendly due to the floating 
boxes graphic but it‟s not very attractive to the eye. This is because Pfizer are 
selling an essential prescription drug and they want to get the important 
information to the viewer as quick and easily as possible.  
 72 
There is a significant differentiation in the three different television commercials. 
The Claritin commercial from 1996 was very surreal, trying to get the viewer to 
go to the doctor and ask for Claritin when it was a prescription drug. The name of 
the drug was constantly repeated throughout the commercial and voiceovers were 
trying to get into the subconscious of the allergy sufferer that this was a great 
idea. This was the same for the Lipitor advertisement. They make use of a current 
user of the drug to bring home to people that this could happen to them and 
encourages them to attend the doctor. John E. resonates with the audience because 
he provides a wake-up call for a serious condition. The message is got across in 
two different methods but the message is clear: Visit your doctor and ask for our 
company‟s drugs. The UK Clarityn commercial is a humorous way of selling a 
non-prescription drug in a quick, fun, bright and get the message across in a short 
space of time whereas the Lipitor commercial is a lot more serious. 
In this analysis of the Lipitor website, no equivalent European website could be 
found. This is due to the ban on direct-to-consumer (DTC) advertising. But I think 
this could change due to the fact that websites that promote prescription drugs can 
be accessed anywhere in the world. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 73 
5.0 Interviews and Analysis 
5.1 Introduction 
Interviews were conducted with a set of customers that the pharmaceutical 
companies target i.e. doctors and pharmacists. Interviews were also done with 
pharmaceutical representatives that promote and sell the products for the 
companies. I also interviewed personnel in industry that deal with the regulatory 
side of marketing, a business effectiveness manager who deals with 
representatives and advertisements and a senior regulatory manager that deals 
with the regulation side of marketing. 
The questions aimed to find out the backgrounds, the influence of pharmaceutical 
representatives through their selling techniques, the information given and the 
importance given to the information provided by the representatives. I also 
wanted to find out how much guidance that healthcare professionals get in 
relation to marketing, the significance of marketing and the challenges in reading 
the marketing materials. In addition, the questions for the healthcare professionals 
are set out to find out the persons opinion on the marketing methods of the 
pharmaceutical companies i.e. pharmaceutical representatives, advertising and 
Direct-to-Consumer (DTC) advertising.  
The questions that were set for the pharmaceutical representatives were to find out 
how they approach customers i.e. doctors and pharmacists, their training, what 
they thought of their jobs in the pharmaceutical industry, other marketing methods 
and bonuses to customers.  
The objective of the interviews is to find out the opinions of different groups of 
people that the pharmaceutical companies target and get to sell their products. The 
interviews conducted are detailed below. All interviewees requested privacy. 
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5.2 Pharmacist Interviews 
5.2.1 Summary 
A set of ten questions were asked to three different pharmacists, branch 
pharmacist, Dublin, hospital pharmacist, Dublin and a rural pharmacist from 
Spain. 
5.2.2 Analysis 
Despite coming from very different backgrounds, i.e. from a hospital setting, from 
a pharmacy on the high street and a rural pharmacy, there are some common 
views from each person. The branch and hospital pharmacists would read the peer 
review papers to get the factual information on the drug being sold. In reading the 
marketing materials, the main challenge would be finding the time.  Also each 
pharmacist had the an opinion about DTC advertising; the branch and hospital 
pharmacist each said it would mislead the consumer as the general public have 
had no training in the differentiation of the numerous drugs on the market and 
their side effects while the Spanish pharmacist said it would only affect the way 
the doctor prescribe as it would take away the power from the doctor.  Again, 
along with the doctors, the pharmacists had no education in the marketing 
techniques from pharmaceutical companies. The branch and hospital pharmacists 
expressed that there should be more legislation about advertising drugs on the 
internet as the information that is given is very unreliable and the Spanish 
pharmacist expressed the view that it was illegal to advertise and sell drugs on the 
internet. Each pharmacist expressed the view that pharmaceutical representatives 
had a useful role in providing information on new drugs and treatments. This is 
the same opinion as the doctors. There is a divergence about the contribution of 
marketing from pharmaceutical companies. The hospital and branch pharmacists 
expressed the views that marketing would mislead the consumer while the 
Spanish pharmacist stated that it provides a conduit for the consumer to ask for 
certain drugs. 
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5.2.3 Transcript of Interviews 
Branch pharmacist, Dublin  
1. What did you study? What is your specialization? 
I have a BSc degree in pharmacy.  I am a supervising pharmacist, which means I 
am head pharmacist for my branch with responsibility for all aspects of the 
dispensary. 
2. When you are working, how often on average do you see a pharmaceutical 
representative? How long would you see them for? 
I would see a rep once a fortnight for dispensary items. They would see the OTC 
(over the counter) manager two or three times a week that deals with everything 
in the shop front. The visits from reps for the dispensary are usually about 10-15 
minutes as it is normally just for placing an order. If they are launching new 
products, it can be a little longer. The reps for OTC medicines etc. normally stay 
longer. 
3. On a general visit from a representative, do you get the impression that the 
information that is given is balanced?  How would they approach you? 
The reps for OTC products are always pushing their product. Most medical reps 
for prescription items have information literature and case studies with them. The 
OTC reps are more biased as pharmacists are free to recommend whatever 
product they wish to the customer. They are pushier as they want the pharmacy to 
stock their particular product. For prescription items, information is more 
factual. However, the literature does tend to portray their product in a positive 
light. As pharmacists have to dispense what doctors prescribe, there is really only 
an opportunity for reps to inform about products rather than trying to push us to 
stock them. Some reps however do try to encourage us to stock their product in 
anticipation of a doctor‟s prescription coming in and will say that certain doctors 
in the area have agreed to/stated they will prescribe the product concerned. 
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4. In your opinion, do you think that information from pharmaceutical 
representatives is important? 
It is an opportunity to ask questions about new products and gain specific 
information about a particular product. If there is a query from a customer about 
a particular product, you can ask a medical rep. It can be useful to have a rep 
explain particular things about specific products in a concise manner e.g. 
demonstrate the correct use of an inhaler, which may not always be so clear from 
just reading a leaflet. In addition, if a rep calls and quickly goes through some of 
the most important points of a product you are more likely to listen rather than 
trawl through all the literature, which can be time-consuming and not always 
feasible. If you put some pushiness to one side, medical reps can be quite useful at 
times! 
5. Have you had any guidance in relation to pharmaceutical marketing? 
In college, no. You pick it up with experience but mostly deal with the information 
that is given with scepticism. It depends on the approach of the rep. You have to 
be aware that the company market their product in order to sell it and while it 
may be a perfectly good product, at the end of the day their goal is to increase 
sales. 
6. Do you believe pharmaceutical marketing contributes to the benefit of the 
consumer? In what way? 
Not always. For example, Calpol sent in an A3 poster because the company 
brought out a new flavour. This poster didn‟t have any real information on it 
except that it had a new flavour and I was meant to put it up in the pharmacy. No 
real benefit to the consumer. This benefits the company rather than the consumer. 
Some marketing can benefit the consumer and the pharmaceutical company e.g. 
advertising about incontinence and thrush can alert people to a problem and 
makes them aware there are treatments available from their GP or pharmacist. 
However in some cases due to intensive marketing e.g. on TV consumers are 
insistent on trying a particular named product even though an equally good 
cheaper product is available or even already been tried. The power of the 
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marketing campaign influences the consumer sometimes more than the advice of 
the healthcare professional, which is no benefit to the consumer. 
7. Do you go through all the marketing material? What would be the main 
challenge for you in reading the marketing material? 
If it was giving information about a new product, I would. It gives new 
information about the drug but as I don‟t prescribe prescription drugs, I only 
dispense them. It helps me to remind the consumer of the side effects and 
precautions. In the future, in my opinion, I would hope there would be a 
partnership with the doctor in prescribing drugs.  At the moment, there is not a 
huge amount of communication between pharmacists and doctors when it comes 
to choosing what doctors prescribe. Therefore, while it‟s important for 
pharmacists to know all the products we don‟t make the decision. If there was 
more communication, as in some other countries and we were involved more in 
prescribing we would be more interested in marketing material to inform us about 
new products and updated information. At the moment I concentrate on reading 
material about products I have patients on or updated safety information. The 
main challenge in reading the material is finding the time. 
8. (a) The EU is thinking of changing the law on DTC advertising on certain 
prescription drugs. What do you think of DTC advertising? (b) Do you think 
it will have an influence on patients decisions/buying power? 
(a) I think it‟s misleading, a little knowledge is dangerous. There will be too much 
pressure on the doctor in which the doctor may think it‟s not the best drug to 
prescribe but will be influenced by the patient. However, on the flipside people 
with conditions will know his/her own medication and use it responsibly. It takes 
control away from health professionals who are properly trained  and puts it into 
the hands of the general public who may not understand that medication has side 
effects and that certain medications do not suit certain people. 
(b) Yes, some people will be taken in by marketing campaigns and may insist on a 
particular medication being prescribed based on what they have seen in 
advertising rather than listening to the heath professional. 
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9. Have you had customers come to you because they saw a drug advertised 
on the internet? Do you think there should be more regulation about 
advertising on the internet? 
Very occasionally people ask about prescription items but normally it‟s about 
herbal remedies or creams. While I think there should be some regulation on 
internet advertising I don‟t see how it would be possible. 
10. Do you think there has been any difference in marketing methods from 
the past? Do you think they have increased the pressure, more to push a 
drug? 
This has not affected pharmacists. Any advertisements come in the post mostly. 
This targets OTC drugs rather than the prescription drugs. Different generic 
companies come to the pharmacy trying to sell their products. They sometimes 
induce the deal with bonuses. The pharmaceutical society has a code of ethics and 
in it; there is a section about not receiving gifts but is not a big influence. 
Hospital Pharmacist, Dublin 
1. What did you study? What is your specialization? 
I have a BSc in pharmacy specialising in hospital pharmacy. I am now working as 
a research fellow. 
2. When you are working, how often on average do you see a pharmaceutical 
representative? How long would you see them for? 
In my role as a hospital pharmacist I would meet them once a month for maybe 
for a half an hour. It depends on the speciality that you work in. In certain areas 
there may be more new drugs coming on the market than others  
3. On a general visit from a representative, do you get the impression that the 
information that is given is balanced?  
No, I would always want to do my own independent assessment. They would 
provide marketing information and published peer review data. This peer review 
data is what I would look at. 
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4. In your opinion, do you think that information from pharmaceutical reps 
is important? 
I think they have useful roles, they provide you with relevant information but it‟s 
not sufficient. Healthcare professionals often do not have enough time to critically 
appraise all the evidence for a new product. Therefore I think we need 
independent information from an independent organisation for healthcare 
professionals to rely on.  
5. Have you had any guidance in relation to pharmaceutical marketing? 
I didn‟t have any guidance but when I worked in the UK there were guidelines for 
reps meeting pharmacists in the hospitals but I am not aware if there are similar 
guidelines in Ireland. 
6. Do you believe pharmaceutical marketing contributes to the benefit of the 
consumer? In what way? 
For the consumer, I think there‟s a risk they would believe everything presented 
by the company and they may not have a balanced view of the benefits/risks 
associated with a particular product e.g. potential side effects with the product 
while the healthcare professional is better qualified to select the most appropriate 
medicine for a particular patient, taking into account benefits, risk and individual 
patient characteristics.  
7. Do you go through all the marketing material? What would be the main 
challenge for you in reading the marketing material? 
I don‟t go through it all. The main challenge would be establishing the truth. I 
would always refer back to the original peer reviewed publications Even then, it 
is important to have the skills to critically appraise the original publications and 
establish the strengths and weaknesses of the particular study.  
8. (a) The EU is thinking of changing the law on DTC advertising on certain 
prescription drugs. What do you think of DTC advertising? (b) Do you think 
it will have an influence on patients decisions/buying power? 
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(a) I wouldn‟t be in favour of it because as I said the consumer isn‟t in the best 
position to select the best products.  
(b) It has an influence on the patients buying power. It could put pressure on the 
healthcare professional. With pharmacists, the consumer would go in asking for 
particular products, rather than requesting advice for the management of 
particular symptoms. 
9. (a) Have you had customers come to you because they saw a drug 
advertised on the internet? (b) Do you think there should be more regulation 
about advertising on the internet? 
(a) No, the patients in the hospital on the ward where I worked were all sedated. 
This would be less likely in the hospital setting because the medical team and 
pharmacist would be regularly reviewing the patients‟ medication. 
(b) Yes, because there is a lot of different sources of information. I think there are 
few resources that can be relied on. I would always go to medicines.ie (published 
by the Irish Pharmaceutical Healthcare Association Ltd). This contains the 
Summary of Product Characteristics (SmPC) for licensed medicines in Ireland 
and accurate information while some other websites can‟t be relied on. 
10. (a) Do you think there has been any difference in marketing methods 
from the past? (b) Do you think they have increased the pressure, more to 
push a drug? 
(a) I have not worked in the hospital setting since 2002 but can imagine that it has 
improved in terms of giving gifts etc. I think that this still goes on but there 
should be less focus on that and more on the educational side. The information 
that is given and the way it‟s delivered could be improved on. I think it would be 
more appropriate for this information to be delivered by an independent 
organisation. 
(b) I think it is their job to do that, make appointments and to come in and make 
the healthcare professional aware. 
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Spanish pharmacist, rural central Spain 
1. What did you study? What is your specialization? 
I have a BSc degree in pharmacy.  My specialisation is in homeopathy. 
2. When you are working, how often on average do you see a pharmaceutical 
representative? How long would you see them for? 
Most information comes in written form as I work in a rural pharmacy. Usually 2 
-3 representatives call every 2 – 3 months. They spend about thirty minutes. 
3. On a general visit from a representative, do you get the impression that the 
information that is given is balanced?  How would they approach you? 
Yes, the information is very good. They usually phone me in advance. 
4. In your opinion, do you think that information from pharmaceutical 
representatives is important? 
Yes, but the information given to doctors who prescribe is more important. 
5. Have you had any guidance in relation to pharmaceutical marketing? 
I didn‟t receive any guidance but there are private courses available to 
pharmacists. 
6. Do you believe pharmaceutical marketing contributes to the benefit of the 
consumer? In what way? 
Yes, I believe that it provides a conduit for the consumer to ask about certain 
drugs. 
7. Do you go through all the marketing material? What would be the main 
challenge for you in reading the marketing material? 
I go through all that I can. Time would be the biggest challenge. 
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8. (a) The EU is thinking of changing the law on DTC advertising on certain 
prescription drugs. What do you think of DTC advertising? (b) Do you think 
it will have an influence on patients decisions/buying power? 
I didn‟t know about this law. Spanish pharmacies generally only stock 
prescription drugs so if it change it would only affect what the doctor prescribes. 
9. Have you had customers come to you because they saw a drug advertised 
on the internet? Do you think there should be more regulation about 
advertising on the internet? 
No. All advertising and selling of prescription drugs is illegal on the internet. 
10. Do you think there has been any difference in marketing methods from 
the past? Do you think they have increased the pressure, more to push a 
drug? 
Marketing methods are now more aggressive. There is a push now towards 
generic drugs to drive down cost. 
5.3 Doctor Interviews 
5.3.1 Summary 
A set of ten questions were set out to three different doctors, a hospital doctor, 
RCSI doctor and a General Practitioner. 
5.3.2 Analysis 
There are commonalities in the answers given by the doctors. Two of them 
independently disagree with Direct-to-Consumer advertising as it will take the 
power of decision out of the doctors‟ hands, into the patient and add to the cost of 
the drugs while the general practitioner said that patients would need more 
guidance towards medicines than just an advertisement. The three doctors have 
had patients come to them asking for drugs that were seen on the internet, so 
already some decision making, be it indirectly, has been removed from the 
doctors decision. The three doctors do see reps on a regular basis, be it for a short 
time, about 10 - 20 minutes (or even more if at meetings or conferences) about on 
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average once a week. The general practitioner actively encourages reps to come 
and see him. The information given is biased towards selling the product but on 
the other hand the opinion is stated that it‟s a new source of information about 
new drugs and treatments so it keeps them up-to-date. 
There is a divergence of opinion about the giving of gifts. The first doctor thinks 
that it does influence the doctors prescribing habits while the second and third 
doctor think that it doesn‟t, even on a personal level.   
Guidance in relation to marketing methods seems to be non-existent in medical 
school. There are medical schools that suggest that their students take an oath not 
to accept gifts as mentioned by the first doctor. Reading the literature seems to be 
a personal decision, but the separating the propaganda from the essential 
information takes time.  
5.3.3 Transcript of Interviews 
Hospital Doctor, Dublin 
1. What did you study? What’s your specialization? 
I studied medicine specialising in anaesthesia. 
2. (a) When you are working, how often on average do you see a 
pharmaceutical representative?  (b) How long would you see them for? 
(a) I see a rep once every ten days to 2 weeks but to be accurate twice a month. 
I‟m not their primary target but they still target me. 
(b) Depends if it‟s a busy day, but on average twenty minutes for a tea break.  
3. On a general visit from a representative, do you get the impression that the 
information that is given is balanced?  
No of course not. They are trying to sell their products. They would keep a 
balance but definitely biased towards their product. 
4. Have you had any guidance in relation to pharmaceutical marketing 
methods? 
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Not when we were studying. I am not aware of any guidelines. Medical reps will 
try to sell their product but there are people who will make the final decision to 
buy the products. I haven‟t gone through any guidelines. 
5. Do you go through the marketing material? What would be the main 
challenge for you in reading all the marketing materials? 
I would always meet them in the seminars and meetings, the medical reps, they 
would be sending out leaflets and studies to back up their efficacy in using their 
product, a study in done in Belgium for example or in Turkey or somewhere using 
this drug and sending me copies of these studies. You have to have your own 
personal way of dealing with this material. When they come up with this product 
you would like to back up you own experience. I don‟t read all of the marketing 
material. 
6. Do you think there has been any difference in marketing methods over the 
years from pharmaceutical companies? Do you feel there’s an increase in 
marketing methods or it is just different? 
Yes. I think they have come up with new methods of marketing. The companies are 
making more use of the internet, email and are more visible in meetings.  A 
couple of years back they were only at major meetings. Now they are even at 
department meetings. There is always a medical rep around, always targeting 
Internal Medicine and paediatrics. She/he is almost part of the team.  with free 
lunches every day. 
7. How important to you is the information from pharmaceutical companies 
to your practice? 
To be honest they are a source of new information, new techniques, new devices 
and new drugs that have might not have captured our attention. If there‟s a new 
drug in the development stage and has a licence, the next day you will hear about 
that drug through pamphlets free samples etc. I have been practising medicine for 
ten years, there was always been a gap between the drug being approved and the 
drug been introduced because people don‟t hear about it and we don‟t know 
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much about it. Now there‟s a lot of competition and a lot more variety so they 
have to release the drug quickly. 
8. The EU is thinking of changing the law on Direct-To-Consumer 
advertising on certain prescription drugs. What do you think of Direct-To-
Consumer advertising? Do you think it will have an influence on patients 
decisions/buying power? 
Medicines in all in all are poisons. If the drugs are not going to be used properly, 
I don‟t think it‟s a good idea to advertise to consumers. I would go to the extreme 
and ban DTC advertising and should only be directed to healthcare professionals 
who would know and appreciate the different information on the drug. The ads on 
the TV, in the paper stating that “this drug will cure your headache in half a 
minute” or “has the best absorption” stuff like that could be misleading to 
consumers and giving false expectations and definitely harming the patient. 
9. (a) Have you had any patients/customers come to you because they saw a 
drug advertised on the internet? (b) Do you think there should be more 
regulation about advertising drugs on the internet? 
Yes, definitely. In the field of anaesthesia, we deal with pain and in out clinic we 
get to see patients with chronic pain and they would be very affected by what they 
see on the television, from what they learnt from relatives and friends and word-
of-mouth. Patients would say to you “This guy tried this drug, can I try it because 
I have similar back pain? However, they there could be a different cause to the 
pain. With the advertisements and word-of –mouth, definitely we see them in the 
clinic. 
(b) I think there should be more of a hard-line about ads for medications. I think 
they should not be allowed to target a person with no medical background. I think 
the companies should be able to target medical professional, I have no problem 
with that. I don't think they should advertise to the layperson who doesn‟t know 
the different between aspirin and paracetamol. This drug is better than that one, 
what‟s true and not true. Unless you have studied about compounds and how the 
drug works, every drug has a side effect. That‟s why you have to prescribe a drug 
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according to the patient. So for example you have a patient who has a liver 
problem or a kidney problem, you will be tailoring a drug according to the side 
effects. This is called the benefit-risk ratio. If the benefit exceeds the risk you give 
them the drug but if it‟s equal or the risk is greater we don‟t give the drug 
depending of course on the case. 
10. (a) Do you receive gifts? (b) In general, would gifts influence or 
change the prescribing habits of doctors? 
(a) When we were medical students we were in the association (Medical Student 
Association), you have a statement that we DO NOT receive gifts or donations 
from pharmaceutical companies. I kept that line for sometime but now I can‟t say 
that I haven‟t but I got a pen here and pad there, usually I don‟t get involved in 
gifts like holidays or sponsorship for a meeting or buying flight tickets to go 
somewhere. 
(b) I think they do, boys love their toys! If company A is always sponsoring you, 
looking out and giving you this and that, sponsoring your exams, courses etc., you 
would be more inclined to favour them. You‟re seeing the name every time, 
subconsciously it‟s there, and what medication will I go for? For example if the 
doctor is prescribing an antacid and has a choice of company A  company B or 
company C and company A is sponsoring the doctor, the doctor would prescribe 
company A‟s drug without studying B or C drugs. They‟re only human beings. 
Doctor, Royal College of Surgeons in Ireland (RCSI) 
1. What did you study? What’s your specialization? 
I am a doctor for six years and I am currently a specialist registrar (SpR) in 
Rheumatology 
2. When you are working, how often on average do you see a pharmaceutical 
representative? How long would you see them for? 
I would see a rep once a week from different companies in rotation. I would see 
them for about five to ten minutes at a time. 
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3. On a general visit from a representative, do you get the impression that the 
information that is given is balanced?  How do they approach you? 
No, of course not.  They would usually ring you. 
4. Have you had any guidance in relation to pharmaceutical marketing 
methods? 
No, nothing at all. 
5. Do you go through the marketing material? What would be the main 
challenge for you in reading all the marketing materials? 
No, I don‟t read any of the marketing material. I only read key papers that are 
published in journals. 
6. (a) Do you think there has been any difference in marketing methods over 
the years from pharmaceutical companies? (b) Do you feel there’s an 
increase in marketing methods or it is just different? 
(a) I don‟t know, I‟m only qualified for six years. I don‟t know what it was like in 
the past. There are key changes happening now, face-to-face contact is lessening 
and may not be as much as it is now in the next couple of years. 
(b) It varies between companies. You would hear from companies selling products 
within your own field. 
7. How important to you is the information from pharmaceutical companies 
to your practice? 
It‟s not very important. 
8. The EU is thinking of changing the law on Direct-To-Consumer 
advertising on certain prescription drugs. What do you think of Direct-To-
Consumer advertising? Do you think it will have an influence on patients 
decisions/buying power? 
I think it‟s dangerous. Absolutely it would have an influence for the worse. I 
wouldn‟t like it ending up like the American situation that direct marketing 
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prescription drugs encourages patients to ask for drugs not appropriate to their 
illness. The drugs might cost more, it would be more profit driven rather than 
healthcare driven. 
9. Have you had any patients/customers come to you because they saw a drug 
advertised on the internet? Do you think there should be more regulation 
about advertising drugs on the internet? 
Yes, I have. I think there should be more regulation. 
10. (a) Do you receive gifts? (b) In general, would gifts influence or 
change the prescribing habits of doctors? 
(a) Small gifts like pens for example would tend to be available at stands at 
conferences. The main sponsorship I suppose for medical doctors would be for 
conferences, in other words you would be invited to an academic conference as 
their guests. The company would pay for your flight and accommodation. 
(b) No, not for doctors. On a personal experience, no. 
General Practitioner, Dublin 
1. What did you study? What’s your specialization? 
I studied medicine. My specialisation is that I‟m a General Practitioner. 
2. (a) When you are working, how often on average do you see a 
pharmaceutical representative?  (b) How long would you see them for? 
(a) I would see representatives 1 -2 times a week. 
 (b) I would see them for approximately ten minutes at a time. 
3. On a general visit from a representative, do you get the impression that the 
information that is given is balanced?  
No I don‟t think it‟s balanced. There is a tendency to single out only aspects of the 
drugs rather than outlining the negative facts regarding the drugs, such as the 
potential side effects or interactions. 
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4. Have you had any guidance in relation to pharmaceutical marketing 
methods? 
Yes and no. I haven‟t received any direct guidance but through generally reading 
supporting evidence-based research throughout my career, have in a way helped 
me in relation to marketing methods because the companies provide more 
references supporting the efficacy or superiority of the drugs being advertised. As 
a result, I can interpret these studies accordingly. 
5. Do you go through the marketing material? What would be the main 
challenge for you in reading all the marketing materials? 
Yes, I go through it all. The main challenge would be to find a balanced 
representation of the drug or evidence regarding mechanisms of action and 
efficacy of the drugs. 
6. (a) Do you think there has been any difference in marketing methods over 
the years from pharmaceutical companies? (b) Do you feel there’s an 
increase in marketing methods or it is just different? 
(a) There are more evidence-based studies and research now, more than back in 
the early 1990‟s when I started working in general practice. 
(b) Yes, there‟s always a constant stream of posters, models, pens, clocks etc. with 
the drug name. 
7. How important to you is the information from pharmaceutical companies 
to your practice? 
The information that they give is very valuable to my practice because I can make 
informed decisions about prescribing drugs on up-to-date information and have 
discussions with the rep on recent developments in medication.  
8. The EU is thinking of changing the law on Direct-To-Consumer 
advertising on certain prescription drugs. What do you think of Direct-To-
Consumer advertising? Do you think it will have an influence on patients 
decisions/buying power? 
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Patients need to be guided more regarding the indications and the dosage of the 
drugs in order to achieve optimum compliance and benefits of the medications. 
9. (a) Have you had any patients/customers come to you because they saw a 
drug advertised on the internet? (b) Do you think there should be more 
regulation about advertising drugs on the internet? 
(a) Yes, it‟s becoming increasingly more common. 
(b) Yes, definitely as patients can be easily influenced by the information supplied 
by the pharmaceutical companies especially with biased information. 
10. (a) Do you receive gifts? (b) In general, would gifts influence or 
change the prescribing habits of doctors? 
(a) Yes I do. Pens, sticky pads, tissues etc. I also receive samples from companies 
but only the relevant samples are kept. These I find useful especially when 
patients come out-of-hours, after the pharmacist is closed, looking for medication. 
(b) However, the tendency for supplying more expensive gifts has been curtailed 
dramatically over the past ten years or so, which I fully agree with as it may 
influence the prescribing habits of some doctors. 
5.4 Pharmaceutical Representatives  
5.4.1 Summary 
Three interviews were done with three different pharmaceutical representatives, 
two General Practitioner representatives and a hospital representative.  
5.4.2 Analysis 
Pharmaceutical representatives receive extensive training before they are allowed 
to approach the doctors. They arrange meetings with doctors through 
appointments and evening meetings and in the case of the hospital representative 
breakfast and lunch meetings. On average the appointments last from 2 minutes in 
the case of the doctors from out-patients to 30 minutes with General Practitioners, 
depending on the day and how busy the doctors are. The other marketing methods 
such as flyers complement the representative‟s work rather than replace. All three 
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stated that they do not offer bonuses because there are regulations against this and 
any bonus does not have any influence on the doctors prescribing habit. 
5.4.3 Transcripts of Pharmaceutical Representative Interviews 
General Practitioner Pharmaceutical Representative 1 
Tell me about your background, qualifications etc.  
My background is I studied business studies and I have been in sales now for over 
10 years. My previous jobs were that I‟ve been a manager in Dunnes Stores, a 
Sales Rep and Territory Sales Manager in Coca-Cola. Now I‟m a Medical 
Representative. 
What training have you received to be a pharmaceutical rep? 
I have received the following education and training in the following: anatomy 
and physiology, product training, Ideals Selling course, IPHA training and I am 
part of the Medical Representative Institute of Ireland (MRII). 
What methods do you use to contact customers? 
I mainly use the phone and calling into the surgery when passing to gain 
appointments which was very useful when becoming a Medical Rep as you got to 
meet with the Practice Manager rather than a phone conversation for the first 
time. I also hold extra evening meetings with a beneficial topic for the 
GP/Practice Manager to help gain access.  
Can you give me an idea about a typical visit e.g. time taken on average, 
approaches etc.  
This depends on the GP and how busy he is but I can get 2 minutes or 30 minutes 
on average. Normally the approach I would tend to take would be a relaxed 
approach as the GP has allowed me the time to detail him/her and has been 
seeing a lot of sick people all day so welcomes a relaxed atmosphere for a short 
while. I go through all the details I feel are beneficial to the GP after gaining 
some knowledge about his/her wants when prescribing the drugs I‟m detailing. I 
adapt the call to their needs. 
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Then I ask for the business because at the end of the day this is the most important 
part of my job. 
In what way your job as rep you think is essential to the pharmaceutical 
industry? 
If you go into a Medical Centre/GP Practice you will see that these are very busy 
places. The GP does not always have the time to be reading up on drugs and the 
rep is fit to call give a description of his/her drug and hopefully influence the GP 
in their prescribing habits. On building relationships with the GPs we definitely 
can convince them to write the drug in question. 
On a daily basis I try to make a difference by influencing the GP and this is 
essential for generating revenue for the company, so that the pharmaceutical 
company can research, create and develop new drugs. Without a reminder to the 
GPs, the drug being detailed could get lost as there are a lot of competitors out 
there looking for the business.    
Do you think other methods of marketing are useful to the industry or they 
are a threat to the rep job? 
Marketing is extremely useful as the GPs like to have something visual. Our 
marketing department is excellent and if the GPs see the marketing materials 
everywhere they are more likely to prescribe the product. We each have a role to 
play into getting the scripts written and in this case the rep and marketing 
complements one another.  
Do you offer bonuses to your customers? Do you think they make a 
difference to your sales? 
No, I don‟t as it is my job to influence the prescribing habits of the GP. The 
pharmacist rep might offer bonuses if there are any available. Bonuses in my 
opinion work with a pharmacist but have no real effect on GPs unless they were 
getting compensated for prescribing certain drugs. 
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General Practitioner Pharmaceutical Representative 2 
Tell me about your background, qualifications etc. 
My background would be in sales spending twenty-three in sales with Unilever. I 
wanted to get into the medical side of the business and have just recently finished 
an anatomy and physiology course and I‟m going to do an MRII exam. 
What training have you received to be a pharmaceutical rep? 
I was with Wyeth and I am currently with Pfizer and the training has been very 
extensive. When I was with Wyeth, I had four weeks of extensive training on 
dealing with people in the industry, on how to conduct business, the codes of 
practice and in the background of the drug I would be selling at the time. 
What methods do you use to contact customers? 
With some of them, you can call without an appointment but it‟s getting harder 
and harder to see doctors. You really have to make appointments to see them now.  
The doctors that are hard to see are the long term customers. When you are 
finished, you make another appointment for three to four months ahead. These are 
termed rolling appointments.  A doctor wouldn‟t want to see you for three to four 
months anyway. Your long term doctors are your „A‟ customers, they do the most 
business. In addition, we would hold different presentation nights on what doctors 
are currently interested in. We would go along on those nights and speak to them, 
an informal way of knowing the doctor, a general chat. The doctors are then 
familiar with me when I come in for the appointment. 
Can you give me an idea about a typical visit e.g. Time taken on average, 
approach etc. 
I‟m conscious that I‟m here to do a job. When I go in and greet the doctor, maybe 
a little bit of chit chat and then you go into the sales presentation.  They might 
know the drug but may have forgotten and they need to know about different 
points. I would probably spend seventy percent of my time on my main core drug, 
twenty percent on my secondary and ten percent on my last drug. It all depends 
on the day etc. it could be a half-hour or five minutes. It‟s not that the five minute 
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is any worse than the half-hour appointment. The half-hour could be chatting but 
the five minutes could be direct selling but it depends on the doctor. Remember 
they are well educated people and respectful and you are taking up their valuable 
time. 
I‟m learning the whole time, something different every day. 
In what way is your job as a rep, do you think is essential to the 
pharmaceutical industry? Do you think other methods of marketing are 
useful to the industry or are they a threat to the rep job? 
Absolutely our job is essential. New drugs have been brought out in the last two 
months and the doctors have never heard of them.  Items coming in, like flyers, 
they don‟t  have time to open it and it probably gets stopped at reception, they 
won‟t read it, won‟t open it and they won‟t know the unique selling points of the 
drug. There is a necessity to have someone to explain it to them. What I find is 
that the drug companies have a lot of people out there not calling just once a year 
but calling on a regular basis to the doctor. Doctors say to me that once the drug 
works and they get familiar with it.  The other methods of marketing, I don‟t think 
so, what the doctor wants to see is a face. 
Do you offer bonuses to your customers? Do you think they make a 
difference to your sales? 
No, the drug sells itself. The guidelines state that you can‟t offer an inducement to 
the doctor; you must focus on the selling. If the drug is good, it will beat any 
inducements. I don‟t think they make impact at all.  
Hospital Pharmaceutical Representative  
Tell me about your background, qualifications etc. 
I studied pharmacology in UCD and I have worked in clinical and regulatory 
affairs before coming a GP rep and just recently a hospital rep. 
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What training have you received to be a pharmaceutical rep? 
I had extensive product training in the summary of product characteristics and 
sales training. I received basic hospital selling skills through being trained in a 
hospital and received further experience from the previous rep when he was 
leaving. 
What methods do you use to contact customers? 
I would hold meetings at breakfast and arrange lunches. I would talk to them over 
the phone and have email correspondence but it‟s mainly face-to-face contact. 
Can you give me an idea about a typical visit e.g. Time taken on average, 
approach etc. 
It depends on the work day of the doctor and varies every day. Sometimes it could 
be lunch for between twenty - forty minutes or maybe just for coffee for about ten 
minutes. The doctors in the out-patients clinic would be for only two minutes. On 
average a visit would be for five to ten minutes.  Ten percent of the time I would 
have to make appointments to see consultants while the rest of the time I would be 
turning up “on-spec”. 
In what way is your job as a rep, do you think is essential to the 
pharmaceutical industry? Do you think other methods of marketing are 
useful to the industry or are they a threat to the rep job? 
Yes, I think it very essential to the industry. The doctors rely on you for 
information about new drugs. I would have clinical research and trials to 
promote the drug. I would be the first port of call for the doctor to be kept 
updated about new treatments and drugs. The doctors can report to me about 
adverse reactions and I can report this to the company straight away. Secondary 
to this would be the sponsoring of their continuing education. I don‟t think other 
methods are taking over; they are generally for product awareness if any.  
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Do you offer bonuses to your customers? Do you think they make a 
difference to your sales? 
No, I just give stationary in order to cut down on department costs. These are just 
kind gestures or to give awareness to the product. They don‟t make any in roads 
to my sales, they‟re only marketing materials. 
5.5 Pharmaceutical Marketing Staff Interviews 
5.5.1 Summary 
Two interviews were preformed with employees that work in the pharmaceutical 
marketing department, a senior regulatory specialist and a business effectiveness 
manager. 
5.5.2 Analysis 
In the interviews that were done with business personnel I found out that there is a 
long process in approving advertisements depending on the change could take up 
to three to six months. The business effectiveness manager has the accountability 
of making sure that the pharmaceutical representatives have been given the right 
information such as the Summary of Product Characteristics and the use of 
marketing materials are being used properly.  The Senior Regulatory Manager is 
responsible for a whole range of marketing aspects from artwork changes and 
issues with Product Authorisation. So companies do take their responsibility 
seriously when marketing drugs to healthcare professionals and have procedures 
in place and a chain of responsibility so that no errors in advertisements can 
violate the regulations and guidelines. 
5.5.3 Transcripts of Industry Personnel Interviews 
Senior Regulatory Specialist, Dublin 
Tell me about your background/qualifications 
My original qualification is a degree in biomedical science and I worked in 
various hospital laboratories. I subsequently studied for and received a PhD and 
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eventually went into regulatory affairs and from there to become a senior 
regulatory specialist. 
What duties does your job involve? 
I‟m responsible for all the regulatory aspects of a portfolio of medicinal products 
for Ireland. This would include managing medical changes, manufacturing type 
changes, artwork changes, interacting with local and global colleagues on 
regulatory, supply chain, marketing and quality related issues, and ensure each 
product is in line with its Product Authorisation and the legislation governing 
medicinal products in Ireland. Part of my day to day work would involve 
interaction and negotiation with the Irish Medicines Board (IMB) on submissions 
or queries that have arisen from same. My role also involves liaising with local 
and global marketing and regulatory colleagues in relation to pipeline products. I 
would also work on less product specific projects, for example rolling out of new 
procedures, specific projects relating to EU legislative or IMB requirements. It is 
also required to keep up to speed on all regulatory requirements and this would 
involve attending Irish Pharmaceutical Healthcare Associated meetings and IMB 
Information Days. 
My role involves quite a broad spectrum; however a detailed level of knowledge 
is required.  
What markets do you deal with? 
I mainly deal with the Irish market but for historical reasons we deal with the 
Maltese market for some products due to the fact that Malta didn‟t have their own 
board of health and therefore needed to use the IMB approval for certain 
products. As well we would deal with South America, the Middle East and some 
countries in Africa. They sell products on the Irish licence through a Certificate of 
Pharmaceutical Product which is based on where the product is manufactured 
and therefore based on the licence issued by the IMB. 
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Does your department oversee pharmaceutical representatives? 
No it doesn‟t but our quality department manages training as part of a Quality 
Management System. In addition regulatory group has a procedure to tell all 
relevant individuals within the business (not just sales representatives) when a 
change happens with a particular product. It is a robust, end-to-end procedure 
which means, employees know when a change is going to happen, know any 
issues during the change; know when it is approved and the timetable for 
implementing it. Our Medical Information Department has the responsibility for 
informing sales representatives and it‟s critical that they know any changes that 
have occurred. The IMB has a programme of inspections and on occasion during 
these inspections the IMB have requested to interview sales representatives about 
their training and knowledge about recent regulatory changes.  
Are there any restrictions on branding, designs, logos etc. 
Yes, and this would be governed by legislation and any changes to packaging 
would need to be approved by the IMB or the European Medicines Agency 
(EMA).   
Which regulations would you follow more closely Irish or European? 
We would follow both but the Irish legislation is that which has been transposed 
into Irish law and reflects EU legislation. A lot of the time there are the 
guidelines, there is a lot of detail in the legislation and therefore the guidelines 
are helpful on a day to day basis. 
How long does it take to approve a regulatory change advertisement? 
This would be hugely variable and it depends on the change and the assessor. 
Usually it would take three to six months but could take up to two years but really 
depends on the change. If the change is substantial it can take a significant length 
of time as the assessment by the Health Authority can take some time to complete 
and questions may arise that need to be addressed by the company during the 
assessment. 
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Do you submit your advertisements to the Irish Medicines Board (IMB)? 
The IMB do not approved advertisements and therefore there is no requirement to 
submit advertisements to the IMB like they do over in the UK to the MHRA. The 
IMB have recently started a programme of monitoring companies‟ advertising 
materials with a view to assessing if there is any non-compliance issues in this 
area.  
How do you update your documents e.g. Patient information Leaflet? 
If the PIL needs to be updated, all versions are in a validated database in which 
they are controlled, annotated and updated. Then they are sent to another part of 
the company to create a “mock-up” for it. The different versions have to be 
strictly controlled.  
Business Effectiveness Manager, Dublin 
Tell me about your background/qualifications. 
I went to UCC in Cork and received a degree in Nutritional science. I then went 
onto do a marketing course in DIT. I started in a pharmaceutical company about 
three years ago as a marketing assistant and was a part-time hospital rep for 
seven months. Then I went onto become a product manager with my present 
company and eventually a Business Effectiveness Manager. I was transferred into 
the Established Product Unit. As part of this I also need to meet fifteen reps to 
ensure that they are promoting the campaign properly and delivering the key 
messages effectively and make sure that they are detailing the doctor in the 
correct manner and using marketing materials in the appropriate way. 
Do you agree with DTC advertising? 
It‟s a very serious thing. If you look at our brochures, our products look the best, 
if you look at our competitors they look the best – so you wouldn‟t know who to 
believe. This is why it‟s best to advertise to just doctors. I think that it does have 
an effect on the ordinary consumer and the changes in the laws for DTC 
advertising is a bad idea.  I think that patients should be given just the important 
information on t he products, as not all doctors do that. 
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Would there be any differences in marketing or branding the drug before 
and after the patent expires? 
There would be some differences.  Coming up to the expiry date, three would be 
an increase in promotion. I know of a drug that was going off patent soon and it 
was great for ten years. There was huge resources allocated to it, every rep was 
selling it but once it came off patent they took the foot off the pedal with the 
marketing and branding. They still have some promotion but not as much as 
before. The reps were moved to the blockbuster, the first drug would be on-patent 
and the second off-patent. There is a push to increase the reputation of a drug 
until it goes off-patent. 
How long after patent does it remain profitable? 
It depends on the drug. The profitability varies with products. Take drugs like an 
anti-depressants company, they hardly lost any customers due to the fact that 
people who use these drugs don‟t like to change drugs. These patients would be 
loyal to the brand and are familiar with it and more inclined to stay with the 
product. When statins and migraine tablets go off-patent, there would be five to 
ten generics launched in the market.  
When does planning start for a post-patent product? 
When a drug with a company was going to expire, there would be about ten reps 
selling it and for a full year a lot of resources were put in to promote it with the 
budget doubled to try and push it as much as possible. 
Does the market leader influence marketing practices? 
The smaller companies can be less compliant but some companies have to be 
totally complaint due to the fact that they are a major company and maybe a 
bigger player. Due to this fact, the IMB are constantly watching us.  We are 
constantly asking ourselves:  how does this ad look to our competitors? Is this 
compliant with the codes? 
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How do you orientate your market research? 
The pharmaceutical companies can only interview doctors one-to-one but we use 
external companies to do market research. They would give an incentive to a GP 
to answer the questions. Example questions are: How often do you prescribe this 
drug? Which one of these products is your favourite? Our products and our 
competitor‟s products would be included. This market research can‟t be disguised 
as a sales promotion – we never say who we are. We include competitor‟s 
products to find out how we are doing in a particular therapeutic area. 
Does the branding add to the final price of the product? 
No it doesn‟t.  The branding is already in the budget of the drug. 
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6.0 Overall Conclusion 
The purpose of this thesis was to investigate the current marketing practices of 
pharmaceutical companies through a literature search, case studies and interviews. 
The literature search focussed on the regulations and guidelines that control the 
promotion of pharmaceutical products in four markets; Europe, United States, 
Japan and Ireland.  
Two case studies were done on two well known drugs, Clarityn and Lipitor. This 
was done through an analysis of their websites, advertising campaigns and then a 
comparison of their different approaches in marketing between a non-prescription 
and a prescription drug. In comparing these two drugs, I found there were 
different ways of advertising drugs, where Claritin (Clarityn) was portrayed as a 
fun and easy drug to take with few side effects but on the other hand Lipitor is 
marketed as a serious drug for a serious condition.   
Interviews were done with three doctors and three pharmacists to find out their 
opinions on current marketing practices of the companies, the influence of gifts 
from pharmaceutical representatives on prescribing or selling particular drugs. 
Also their opinions were sought on Direct-to-Consumer (DTC), internet 
advertising, and how this effects and controls their decisions on prescribing or 
selling particular brands of drugs. In doing these interviews the healthcare 
professionals met with representatives for 15 -30 minutes on average; independent 
assessments must be performed on information given by representatives but 
information from representatives is still important.  Marketing in general, does 
influence consumer choices and direct-to-consumer (DTC) advertising is 
generally a bad idea. In opinions expressed by the doctors, the internet does have 
a big influence with patients but there is a mixture of opinions on gifts in the 
influence of doctor‟s prescribing habits. 
Interviews were also done with three pharmaceutical representatives to find out 
their opinions on their own positions within the pharmaceutical industry, their 
backgrounds, and their individual approaches in selling their particular products. 
Further opinions were sought from personnel from industry, a business 
effectiveness manager and a senior regulatory specialist. In these interviews, I 
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found several commonalities. Representatives have intensive training and they 
arrange meetings through appointments and presentation meetings. The 
appointments on average last from 5 minutes to 30 minutes and the opinion on 
other marketing methods i.e. flyers, advertisements etc. complement the 
representatives work.  No bonuses are offered due to the fact that it is against 
regulations and they don‟t work. 
Future work 
There could be an investigation into the effect of social websites and how the 
pharmaceutical company is interacting and giving advice to patients and 
customers. This study may perhaps include what possible regulations and 
guidelines that could be implemented.  An investigation into how companies are 
using the digital social media like Facebook and others could be part of this study. 
Overall Comments 
Pharmaceutical products are a special category of merchandise, both due to 
exceptional business risks in development and the need for highly educated 
personnel i.e. doctors and pharmacists to ensure their proper use. The marketing 
of pharmaceutical products is therefore a highly regulated business. This is to 
protect the end user, the patient.  
Marketing and advertising in the pharmaceutical industry are regulated by a 
number of organisations. Legislation in each market is a basis for the guidelines 
set down from these organisations. These guidelines govern different aspects of 
marketing pharmaceutical products from pharmaceutical representatives to 
providing meals. In my analysis of the ethics of marketing, companies that do 
transgress the regulations and guidelines and get punished accordingly.  
Pharmaceutical marketing and promotion provides value to healthcare 
professionals i.e. pharmacist and doctors, by providing highly regulated 
educational and scientific information about new medicines. However marketing 
of new medicines by pharmaceutical companies is only one factor considered by 
healthcare professionals. The marketing does not exist alone, the judgement and 
experience of the professional, with many other sources of information such as 
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peer-reviewed papers and studies plays a large role in determining what medicine 
a patient receives. While pharmaceutical marketing through pharmaceutical 
representatives is not the only source of information for doctors and pharmacists, 
it plays an important role in providing information about the medicines, such as 
adverse reactions, contradictions etc. and helps play a role in providing the best 
treatment for the patient. 
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